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potent! trigger! for! inflammation! and! thrombosis.!Modulating! the! purinergic! signaling!
pathway! is! the! plasmalemmal! ectonucleotidase,! CD39/NTPDase1! (ectonucleoside!
triphosphate! diphosphohydrolase).! ! CD39! is! expressed! by! a! number! of! cell! types!
including!endothelial!cells,!B!and!T!lymphocytes,!and!monocytes!and!macrophages.!It!




ischemia! of! various! organs,! the! coexisting!pathways! of! inflammation! and! thrombosis!
contribute!to!disease!progression.!As!such,!those!enzymes!and!key!steps!in!the!various!
signaling! pathways! involved! in! inflammation! and! those! involved! in! coagulation! are!
targets!for!future!therapies.!CD39!is!one!such!enzyme,!which!can!modulate!purinergic!
signaling!pathways!to!limit!thrombosis!and!inflammation.!
Interest! in!CD39!and! its! function!has!grown!since! its!discovery,! and!much!has!
been!learned!about!its!protective!role!against!thrombosis,!its!sequence!and!structure,!its!
activity!under!targeted!mutations,!and!its!role!in!inflammatory!and!thrombotic!disease!
models.! There! remain,! however,!many! gaps! in! our! basic! knowledge! about!CD39.! To!
address! these! gaps! and! to! contribute! in! a! meaningful! way! to! the! body! of! work!
surrounding! CD39,! three! projects! were! designed,! focused! on! regulation! of! CD39! on!
both!the!transcriptional!and!translational!levels!as!well!as!its!in#vivo#actions.!!
 ix 
! The! work! presented! here! investigates! the! possibility! of! pharmacologically!
regulating!expression!and!activity!as!well!as!the!microenvironment!in!which!it!resides.!
Furthermore,! these! experiments! address! the! issue! of! how! this! regulation! might!










The! overarching! aim! of! this! thesis! is! to! identify! regulatory! transcriptional! and!




Adenosine! triphosphate,! or! ATP,! was! discovered! in! 1929,! far! before! the!
discovery! of! CD39! and! its! ATP/ADPase! activity,! and! before! the! concept! that! purine!
compounds! can! act! as! extracellular! signaling! molecules.! It! was! first! isolated! from!
muscle!tissue!by!Karl!!Lohmann!(1),!and!then!in!1941,!intracellular!ATP!was!found!to!be!
the!main!energy!transfer!molecule!of!cellular!metabolism!by!Fritz!Albert!Lipmann!(2).!
The! earliest! evidence! for! the! physiologic! effects! of! adenineLbased! compounds! in! the!
extracellular! milieu! came! later! that! same! year,! when! the! effects! of! adenosine! and!
adenylic!acid! (adenosine!monophosphate,!AMP)!were! tested!upon!mammalian!hearts!
(3).! By! 1945,! apyrases,! enzymes! that! break! down!ATP! and! ADP! but! are! resistant! to!
inhibition!by!other!ATPLase!inhibitors,!were!isolated!from!potatoes!(4).!!
Evidence! that!extracellular!nucleotides!could!act!as! signaling!entities,!however,!
came! much! later! in! 1970,! when! Burnstock! et! al.! demonstrated! that! ATP! was! likely!
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acting! as! a! neurotransmitter! in! the! gut! (5).! Receptors! for! adenosine! and! ATP! were!
identified! soon! thereafter,! and! named! P1! and! P2! respectively! (6).! P1! receptors! are!G!
proteinLcoupled!receptors!and!are!divided!into!4!receptor!subtypes:!A1,!A2A,!A2B,!and!A3.!
The!P2!family!was!further!categorized!as!P2X!and!P2Y!based!on!receptor!morphology.!
The! P2X! receptor! family! includes! 7! members,! P2X1! through! P2X7.! These! are! purineL
gated! ion! channels! permeable! to! small! monovalent! cations! such! as! sodium! and!
potassium,!with!some!permeable!to!calcium!(7).!These!receptors!form!channels!as!either!
homomeric! or! heteromeric! multimers.! The! P2Y! receptor! family! is! composed! of! G!
proteinLcoupled! receptors! (8).! These! receptors! have! the! classical!GPCR! structure! of! 7!










the! nervous! system,! and! signaling! studies! on! P2! receptorLmediated! pathways! have!
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receptors.! Conversely,! there! exist! endogenous! danger! signals! termed! damageL
associated!molecular!pattern!molecules!(DAMPs)!that!indicate!that!cellular!damage!has!
occurred,!and!are!in!place!to!initiate!an!immune!response.!These!molecules!are!largely!
intracellular! components,! and! examples! of!DAMPs! include! extracellular!DNA,! RNA,!
and! ATP.! The! large! concentration! gradient! that! exists! between! the! intracellular! and!
extracellular! compartments! for! ATP,! favors! a! release! of! ATP! in! those! circumstances!
where! the!cell!plasma!membrane! is!perturbed,!either!by!shear! forces,! injury,!or!death!
(15).! In! the! case!of! cellular!damage! leading! to!ATP! release,!P2X7! receptors,!which!are!
expressed! on! granulocytes,! monocytes,! macrophages,! and! BL! lymphocytes! (16),! and!
which! are! attuned! to!high! concentrations! of!ATP,! are! activated.!The!binding!of! these!
receptors!triggers!signaling!that!induces!the!release!of!proLinflammatory!cytokines!such!
as! ILL1β.!Here,!binding!of!ATP! to! its! receptor!opens! the!P2X7! ion!channel!and!allows!
efflux!of!potassium!ions,!which!triggers!the!NALP3!inflammasome,!the!recruitment!of!




on! the! surface!of!platelets! to! activate! them!and! thus! induce!platelet! aggregation! (19).!
Further! release! of! ADP! from! dense! granules! of! platelets! also! induces! aggregation.!
Several!antagonists!for!P2Y12!receptors!have!been!developed!to!block!this!pathway,!such!
as! clopidogrel! and! prasugrel,! in! the! treatment! of! acute! coronary! syndromes,! and! the!
prevention! of! further! ischemic! events! (20).! These! drugs! belong! to! the! thienopyridine!












CD39,! was! first! detected! in! a! slurry! of! EpsteinLBarr! virusLstimulated! BLcells,! and!
initially!thought!to!be!a!receptor!for!homotypic!B!cell!adhesion!(21).!!The!primary!role!of!
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CD39!was!determined! in! 1996!when!work!by!Wang! et! al.! first! established! that!CD39!





CD39! contains! 6! sites! of! glycosylation! and! a! palmitoylated! NLterminus! that!
preferentially!targets!CD39!to!cholesterolLrich!subcellular!domains!called!caveolae!(25).!
CD39!protein! is!modified!with!NLlinked!glycans! in! the!endoplasmic!reticulum,!which!
ensure! correct! folding! of! the! protein,! and! are! necessary! for! surface! localization! and!
maximal!apyrase!function!(26).!!
Caveolae,! a! subset! of! lipid! rafts,! are! omega! (Ω)Lshaped! structures! enriched! in!
caveolin! proteins,! and! are! thought! to! be! “signaling! platforms”! that! coordinate! cell!
signaling! (27).!Within! these! domains,! CD39! is! coLexpressed!with! ectoL5’Lnucleotidase!
(CD73),! a! glycosyl! phosphatidylinositol! (GPI)Lanchored! cell! surface! enzyme! that!
phosphohydrolyzes!AMP!to!generate!adenosine!(28).!Adenosine!can!bind!P1!adenosine!
receptors,!which! are! expressed!on! leukocytes,! lymphocytes! and!platelets,! to! suppress!
the! release! of! proLinflammatory! cytokines,! inhibit! platelet! aggregation,! and! act! as! a!
vasodilator.! Adenosine! binding! to! the! P1! receptor! subtype! A2A,! for! example,! can!
suppress! the! release! of! cytokines! such! as! tumor! necrosis! factor! alpha! (TNFLα),!
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interferon! gamma! (IFNγ),! and! ILL12! (29).! Ligand! binding! to! A2A! and! A2B! subtypes!
inhibits!platelet!aggregation!by!elevation!of!intracellular!cAMP!caused!by!activation!of!
adenylate!cyclase!(30).!Ligand!binding!to!A2A!receptors!can!also!stimulate!vasodilation!
through! the! activation!of! adenylate! cyclase! (31).! Therefore,! the! signaling! cascade! that!
depletes! extracellular! ATP! and! ADP! is! completed! with! the! formation! of! adenosine,!
which!stimulates!pathways!that!limit!inflammation.!
With! its!ability! to! locally!control!extracellular! levels!of!ATP!and!ADP!and!thus!










being! a! disease! of! inflammation.! Circulating! low! density! lipoprotein! (LDL)! activates!
macrophages! and! the! endothelium,! thus! stimulating! the! expression! of! cellLsurface!
adhesion! molecules! such! PLselectin,! vascular! cell! adhesion! molecule! 1! (VCAM)L1,!
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intercellular!adhesion!molecule!1!(ICAML1),!platelet!endothelial!cell!adhesion!molecule!
1! (PECAML1),! and! junctional! adhesion! molecules! (JAMs)! (35).! Activated! endothelial!
cells!release!PLselectin!that!is!stored!within!WeibelLPalade!bodies.!These!selectins!bind!
PLselectin! glycoprotein! ligandL1! (PSGLL1),! which! is! expressed! on! leukocytes! and!
lymphocytes.! The! binding! of! selectin! to! its! ligand! allows! for! rolling! adhesion! of!
monocytes! along! the! endothelium.! ! Further! interactions! with! adhesion! molecules!
strengthen! adhesion! to! tether! monocytes! to! the! endothelium.! Binding! to! JAMs!
facilitates!leukocyte!transmigration!across!the!endothelial!layer!into!the!subendothelial!
space! (36L39).!Here,! these!monocytes!mature! into! foam! cells,!which! absorb! and! store!
excess! cholesterol,! and! over! time! become! the! core! of! the! developing! atherosclerotic!
lesion.!As!the!severity!of! the!plaque!grows,!so!too!does!the! likelihood!that! the!plaque!
will! rupture,! thereby! releasing! the! contents! of! the! plaque,! which! can! trigger! a!
thrombogenic! response.! Platelets! are! activated,! leading! to! platelet! granular! secretion.!
The! contents! of! platelet! granules! include! many! proLinflammatory! and! platelet!
activating! factors.! Dense! granules! release! ATP! and!ADP,! and! alpha! granules! release!
coagulation! factors! such! as! factor! V,! and! cell! adhesionL! and! coagulationLpromoting!
proteins!such!as!von!Willebrand!factor,!fibrinogen,!PLselectin,!and!platelet!factor!4!(40,!
41).!!
Thrombi! released! from! these! events! can! then! travel! to! other! areas! through! the!
vasculature! and! cause! further! injury,! including! cerebral! ischemia,! as! they! are! able! to!
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impede! blood! flow! supplying! the! brain.! Cerebral! ischemic! events! can! be! initiated! in!
other!ways!as!well,!including!plaques!within!cerebral!vasculature.!Such!ischemic!events!
can! then! trigger! proLinflammatory! signaling,! beginning! with! the! release! of! proL
inflammatory! cytokines! from! resident! microglia! and! cerebral! endothelium.! These!
signals! include! IL1Lβ!and!TNFLα! (42L44),!which! recruit!macrophages!and!neutrophils,!
which!then!release!even!more!cytokines.!Further!injury!comes!in!the!form!of!permeable!
endothelial!barriers,!which!leads!to!greater!fluid!accumulation!in!injured!areas!as!well!
as! the! extravasation! of! leukocytes! into! the! subendothelial! space! and! migration! into!
tissue!parenchyma.!!
Inflammation!contributes!to!thrombotic!events!occurring!in!the!venous!system!as!
well.! Deep! vein! thrombosis! (DVT)! occurs! in! deep! veins! found! within! groups! of!
muscles,! and!most! often! in! lower! extremities.! ! Venous! thrombi! occur! in! vein! valveL!
pockets,!where!the!core!of! the!main!erythrocyte!mass! is!covered!in! layers!of!platelets,!
leukocytes,!and!fibrin!(45).!Originally,!the!cause!of!DVT!was!thought!to!center!on!three!
factors!in!Virchow’s!triad:!stasis,!endothelial! injury,!and!hypercoagulability.!However,!
newer! research! supports! the! contribution! of! inflammation! to! DVT.! These! data! show!
that! cell! adhesion!molecules! and! selectins! that! allow! transmigration! of! leukocytes! as!
described! above! are! also! involved! in! the! development! of! venous! thromboembolism!
(VTE)!(46).!
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The! processes! of! inflammation! and! coagulation! are! necessary! functions.! The!
recruitment! of! leukocytes/lymphocytes! such! as! dendritic! cells,! macrophages,! and! TL
cells,! for! example,! are! necessary! to! detect! and! kill! infected! cells.! Intact! hemostatic!
function!is!also!necessary!in!order!to!repair!damaged!blood!vessels.!Under!pathological!
conditions! such! as! those! described! previously,! however,! the! dual! pathways! of!
inflammation! and! thrombosis! have! been! demonstrated! to! contribute! to! disease!
progression.!As!such,! those!enzymes!and!key!steps! in! the!various!signaling!pathways!
involved!in!inflammation!and!those!involved!in!coagulation!have!been!targeted!as!part!
of!efforts!to!limit!inflammation!or!thrombosis,!respectively.!CD39!is!one!such!enzyme,!
which! can! modulate! purinergic! signaling! pathways! to! limit! thrombosis! and!
inflammation.!
Why!is!there!a!need!for!further!research!on!CD39!and!purinergic!signaling,!given!
that! there!are!antiplatelet! therapies!available?!One! limitation! to! these! therapies! is! that!
there!are!known!resistances!to!antiplatelet!drugs!such!as!clopidogrel,!which!irreversibly!
inhibits!ADPLactivated!P2Y12!receptors.!Resistance!is!due!to!natural!polymorphisms!in!
the!population! in!genes! that! encode! cytochrome!P450! (CYP)! eyzymes! (47),!which! are!
necessary! to!convert! the!proLdrug! into! its!active! form.!Both! the!pharmacokinetics!and!
the!pharmacodynamics!of!clopidogrel!are!affected!in!patients!carrying!reducedLfunction!
CYP2C19! alleles! (48,! 49).! Other! limitations! include! risk! of! uncontrolled! bleeding! and!
delays! due! to! the! time! required! to! metabolize! the! drug.! Most! importantly,! while!
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antiplatelet! drugs! such! as! clopidogrel! and! prasugrel! (another! P2Y12! antagonist)! do!
prevent!platelet!aggregation,!they!do!so!at!the!expense!of!normal!hemostatic!function.!
In! contrast! to! thienopyridineLclass! antiplatelet! drugs,! whose! irreversible! binding! of!
P2Y12! receptors! renders! platelets! permanently! inactive,! the! mechanism! of! CD39’s!
enzymatic! depletion! of! ADP! is! able! to! limit! platelet! aggregation! while! preserving!
normal!platelet!function.!!
Interest!in!CD39!and!its!function!has!grown!since!its!cloning,!and!much!has!been!
learned! about! its! protective! role! against! thrombosis,! sequence! and! structure,! activity!
under! targeted!mutations,!and!role! in! inflammatory!and! immune!disease!models! (50L
52).! There! remain,! however,! many! gaps! in! our! basic! knowledge! about! CD39.! For!
example,!apart!from!a!publication!from!this!lab!in!2010,!nothing!was!known!about!the!
transcriptional!regulation!of!CD39,!and!apart!from!a!publication!from!this!lab!in!2013,!
there! is!next! to!nothing!known!about! the! turnover!of!CD39!and!mechanisms!of!CD39!
degradation.!To!address!these!gaps!and!to!contribute!in!a!meaningful!way!to!the!body!
of!work!surrounding!CD39,!three!projects!were!designed.!The!overarching!aim!of!this!
thesis! is! to! identify! regulatory! transcriptional! and! posttranslational! mechanisms!
governing!CD39,!and!to!identify!their!relevance!in#vivo.!!
My! early! project! began! by! observing! CD39! responses! to!HMGLCoA! reductase!
inhibitors! (statins).! This! class! of! drugs! remains! in! use! by! a! significant! portion! of! the!
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aging!population,!not!in!the!United!States!alone,!but!all!over!the!world.!They!are!used!
to! limit! cholesterol! biosynthesis,! and! their! main! mechanism! of! action! is! inhibiting!
HMGLCoA! reductase,! the! enzyme!which! controls! the! rateLlimiting! step! of! cholesterol!
synthesis! in! the!mevalonate! pathway.! !Here,! 3LhydroxyL3methylglutarylLCoA! (HMGL
CoA)! is! reduced! to! mevalonic! acid! and! CoA! by! HMGLCoA! reductase,! ultimately!
leading!to!the!downstream!synthesis!of!cholesterol.!Statin!drugs!inhibit!mevalonic!acid!
synthesis! by! binding! the! active! site! of! HMGLCoA! reductase,! thereby! inhibiting! the!
remainder!of!the!mevalonate!pathway.!!
While! statins! as! a! class! of! drugs! has! been! shown! to! be! an! effective!means! of!
lowering! serum! cholesterol,! the! pleiotropic! actions! of! these! drugs! are! also! wellL
documented! (53,! 54).! For! example,! in! the! presence! of! statins,! downstream! reactions!
from! the! mevalonate! pathway! that! generate! isoprenoid! intermediates! such! as!
geranylgeranyl! pyrophosphate! (GGPP)! and! farnesylpyrophosphate! (FPP)! (55)! are!
disrupted.! These! lipid! intermediates! serve! as! covalently! bonded! posttranslational!
modifiers! of!members! of! the! Ras! superfamily! of! small! GTPases,!which! includes! Ras,!
Rho,!and!Rab!families!of!proteins.!Ras!family!members!act!as!molecular!switches!that!








also! initiated! based! on! findings! from! our! work! describing! the! role! of! cAMP! in!
modulating!CD39! (59).! !Although!several!potential! regulatory!sites!were! found! in! the!




protein! kinase! (PKA),! leading! ultimately! to! the! binding! of! cAMP! response! element!
binding!protein!(CREB)!to!the!CreLlike!sequence.!!
Based! on! this! work,! we! hypothesized! that! cAMPLmodulating! drugs! might! be!
able! to! modulate! CD39! expression! levels.! This! raises! the! possibility! of! repurposing!
currently! used! drugs! to! modulate! endogenous! levels! of! CD39.! ! Phosphodiesterases!
(PDE)! are! enzymes! that! hydrolyze!phosphodiester! bonds! that! are! found! in! the! cyclic!
nucleotides! cAMP! and! cGMP.! ! As! cAMP! and! cGMP! are! both! ubiquitous! second!
messengers! that! mediate! pathways! involved! in! inflammation,! oxidative! stress,! cell!
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proliferation,!vasodilation,!and!platelet!activation,!PDEs!play!an! important! regulatory!
role! in! intracellular! signaling! and! continue! to! be! investigated! as! therapeutic! targets.!
Different!phosphodiesterase!family!members!have!varying!affinities!for!bonds!present!
in! cAMP! versus! cGMP.! The! PDE! superfamily! contains! 11! different! families! of! PDEs!
(PDE!1L11),!each!of!which!contain!multiple!splice!variants.!Of!these,!PDE!families!1L4,!
7,8,10,! and! 11! can! hydrolyze! cAMP! (60,! 61).! Two! drugs! that! inhibit! the! enzyme!
phosphodiesterase! III! (PDEIII),! cilostazol! and! milrinone,! were! chosen! to! test! the!
hypothesis! that! cAMP!modulating!drugs!might!be!able! to!modulate!CD39!expression!
levels.! Each! has! been! approved! for! humans,!with! cilostazol! used! in! the! treatment! of!
intermittent! claudication! caused! by! peripheral! artery! disease! and! milrinone! in! the!
treatment!of!heart!failure.!!
The! results! of! this! project! were! surprising! in! that! CD39! was! found! to! be!
differently! regulated! by! PDE3! inhibition! in! endothelial! cells! versus! macrophages.! In!
macrophages,!regulation!is!at!the!level!of!transcription,!but!in!endothelial!cells,!this!was!
not! the! case,! as! there!were!no!differences! in!mRNA! levels!between! cells! treated!with!
cAMP!or!cilostazol.!The!difference!in!responses!between!macrophages!and!endothelial!
cells! prompted! investigation! into! the! mechanism! through! which! endothelial! CD39!
protein! might! accumulate! in! response! to! elevated! cAMP! levels.! Results! from! this!
investigation!provide!novel! insights! into!CD39!posttranslational! regulation.!Together,!
the!conclusions!of!this!study!indicate!that!CD39!protein!can!be!elevated!using!existing!
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CD39,! an! enzyme! expressed! on! the! plasma!membrane! of! endothelial! cells! and!
leukocytes,!phosphohydrolyzes!ATP!and!ADP!to!generate!AMP.!CD39! is! thus!able! to!
limit! local! levels! of! extracellular! ATP! and! ADP,! which! are! potent! promoters! of!
inflammation! and! platelet! aggregation.! This! action! has! implications! for! a! number! of!
disease! states,! including! atherosclerosis.! HMGFCoA! reductase! inhibitors! (statins)!
protect! against! atherosclerosis! by! inhibiting! cholesterol! synthesis,! but! they! also! limit!
inflammation!and!thrombosis,!the!mechanistic!basis!of!which!are!not!fully!understood.!
We! hypothesized! that! if! CD39! expression!were! regulated! by! statins,! it!may! underlie!
some!of!these!pleiotropic!protective!mechanisms!of!statins.!
CD39! is!known!to!be! targeted! to!caveolae,! invaginated,!cholesterolFrich!plasma!
membrane! domains! linked! to! many! cellular! processes,! including! endocytosis,!
transcytosis,!and!various!signaling!pathways.!The!formation!of!caveolae!depends!on!the!
presence! of! caveolin! proteins,! which! associate! with! each! other! and! with! cholesterol.!
When! treated!with! the!statin! fluvastatin! (10!mM,!24!hrs),! compared! to!control!DMSO!
treatment,! human! umbilical! vein! endothelial! cells! (HUVECs)! exhibit! a! significant!
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decrease! in! caveolinF1! (67%,! p<0.05,! n=4).! HUVECS! treated! with! fluvastatin! exhibit!
significant!increases!in!CD39!mRNA!(13Ffold,!!p<0.01!n=7),!protein!(8.1Ffold!over!DMSO!
treatment,!p<0.01,!n=4)!and!activity!(2.1Ffold).!CD39!mRNA!and!protein!levels!increase!
doseFdependently! in! response! to! fluvastatin! treatment! (0.1,! 1,! 10,! 25\M).! An! siRNA!
construct! was! highly! effective! in! silencing! CavF1! mRNA! (85%! reduction! in! CavF1!
mRNA! and! protein),! and! CD39! mRNA! and! protein! levels! were! unaffected! by! Cav1!
mRNA!levels.!Silencing!Cav1!mRNA!also!did!not!prevent! fluvastatin! from! increasing!
CD39!mRNA!and!protein!(12F!and!12Ffold!respectively).!These!data!indicate!that!Cav1!
levels!do!not!modulate!CD39!mRNA!or!protein.!However,!the!question!of!whether!the!





ATP! is!a!biologically!critical!molecule! that!has!distinct! functions!depending!on!
where!it! is!found.!When!compartmentalized!within!the!intracellular!environment,!it! is!
used!as!an!energy!source,!but!when!released!in!the!extracellular!milieu,!it!signals!injury!
and! promotes! platelet! activation,! platelet! aggregation! and! inflammation! (1F3).! As!
discussed! in!Chapter! I,!CD39! is!a!nucleotidase!expressed!on!the!plasma!membrane!of!
endothelial!cells!and!leukocytes,!and!it!terminally!phosphohydrolyzes!ATP!to!generate!
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ADP! and! AMP! (2,! 4F12).! This! ectoFenzyme! is! coFexpressed! in! plasmalemmal!
microdomains!called!caveolae!with!CD73!(13),!another!ectonucleotidase!that!hydrolyzes!
AMP!to!adenosine.!Through!this!cascade!mechanism,!CD39!is!able!to!locally!dissipate!





Atherosclerosis! is! a! cardiovascular! disease! wherein! blood! vessels! narrow! as! a!
result! of! cholesterolFrich! plaque! deposition,! with! both! coagulation! and! inflammation!
contributing!to!its!progression!(1,!3,!18,!19).!It!is!one!of!the!leading!causes!of!death!in!the!
US,! and!of! the!population!between! the!ages!of! 40!and!75!who!have!or! are!at! risk! for!
cardiovascular! disease,! the! majority! of! patients! are! prescribed! HMGFCoA! reductase!
inhibitors! (statins)! (20),! a! class! of! drugs! that! limit! cholesterol! synthesis.! Numerous!
studies!over!recent!years,!however,!have!shown!that!statins!are!beneficial!independent!
of!their!known!property!to!inhibit!the!rateFlimiting!step!in!cholesterol!synthesis!(21F25).!
For! example,! they!protect! against! inflammation! and!platelet! aggregation! (4,! 23),! help!
preserve! endothelial! function! (26F28),! promote! neovascularization! of! ischemic! tissue!
(29),! and! inhibit! plaque! rupture! (30).! The! question! of! how! statins! exert! these! many!
pleiotropic! effects! remains! largely! unanswered,! and! the! importance! of! investigating!
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these! independent! mechanisms! is! growing,! not! only! due! to! interest! from! a! basic!
scientific! point! of! view,! but! also! to! the! increasing! prevalence! of! statin! use! at! the!
population!level,!and!the!large!population!burden!of!atherosclerotic!disease.!The!study!
of! the!myriad!downstream!effects!of!statins! is!not!only! informative!about!how!statins!
work,! but! also! about! how! these! statinFdriven!mechanisms! can! best! be! utilized! in! the!
search!for!novel!therapeutic!strategies.!Therefore,!this!project!aims!to!establish!whether!
statins!can!act! independently!of! their! lipidFlowering!effects,! through!CD39!regulation,!




cholesterol! transport,! and! numerous! signaling! pathways! (31F42),! and! caveolae! in!
endothelial! cells! have! been! shown! to! contribute! to! the!progression! of! atherosclerosis.!
Previous!studies!have!demonstrated!that!CD39!is!targeted!by!way!of!palmitoylation!to!
caveolae! (6),! where! the! coFlocalization! of! CD39! and! CD73! allows! the! coordinated!
breakdown! of! ATP! down! to! adenosine.! The! concerted! action! of! this! enzyme! pair!
restores! vascular! homeostasis,! by! dissipating! ATP! and! ADP! (proFinflammatory! and!
proFcoagulant! signals)! as! well! as! by! increasing! the! antiFinflammatory! and! the!
endothelialFprotective! signal! of! adenosine! (2,! 3,! 12,! 15).! The! formation! of! caveolae!
requires! the! presence! of! caveolin! proteins,!which! associate!with! each! other! and!with!
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cholesterol! to! form! endocytic! vesicles! that! bud! into! the! cell! surface,! resulting! in! the!
invagination! of! the! plasmalemma.! Proteins! that! are! targeted! to! caveolae! are! already!
present! in! these! endocytic! vesicles! (proFcaveolae),! and! their! targeting! to! caveolae! is!
often! determined! by! postFtranslational! modifications! (e.g.! palmitoylation).! In!
endothelial! cells,! the! predominant! caveolin! proteins! are! caveolinF1! and! F2,! with!
caveolinF1! determining! whether! caveolae! will! form! and! with! caveolinF2! serving! a!
relatively!minor! role! in!determining!caveolar!morphology.!When! treated!with!statins,!
caveolinF1! expression! in! endothelial! cells! has! been! shown! to! decrease! (42).! Our! data!
show! that! CD39!mRNA,! protein,! and! activity! all! increase!with! statin! treatment,! and!
others! have! shown! that! CD39! remains! inactive! until! it! has! reached! the! plasma!
membrane! (7).! These! data! suggest! that! CD39! is! capable! of! residing! on! the! plasma!
membrane,! independent! of! caveolae,! and! that! normal! trafficking! of! CD39! may! be!
altered!in!the!presence!of!statins.!!
To!date,!the!specific!role!of!the!caveolar!microenvironment!in!determining!CD39!
activity,! and! the!physiological! relevance!of! statinFmediated!disruption!of! caveolae! for!
CD39!function!and!events!downstream!thereof!are!unknown.!In!endeavoring!to!answer!
these!questions,!the!intent!of!this!project!is!to!further!our!knowledge!about!the!enzyme!
CD39,! which! plays! a! demonstrably! critical! role! in! inhibiting! inflammation! and!
coagulation.! The! research! presented! below! addresses! the! possibility! of!
pharmacologically! regulating! CD39! and! the! microenvironment! in! which! it! resides.!
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Furthermore,! these! experiments! address! the! issue! of! how! the! presence! of! statins! and!
regulation! of! the! CD39! microenvironment! might! modulate! the! capacity! of! CD39! to!










with! collagenase! III,! and! the! open! end! held! shut! with! sterilized! hemostatic! clamps.!
Cords!were!left!to!digest!at!37!°C!for!15!minutes.!Collagenase!from!veins!was!collected,!
diluted!with!more!isotonic!buffer,!and!centrifuged!for!4!minutes!at!4!°C!and!190!x!g.!The!
resulting! pellets! were! gently! resuspended! in! complete! growth! media! composed! of!









volumes! of!DMSO.! Pravastatin!was! also! used! as! a! control,! as! the! highly! hydrophilic!
nature! of! pravastatin! prevents! its! uptake! by! cells,! and! can! thus! serve! as! a! control!

















layer! chromatography! (TLC),! to!measure! differences! in!ATP! phosphohydrolysis! as! a!
measurement! of! CD39! activity! (44).! Cells! were! incubated! with! [8F14C]ATP! in! the!
presence! of! the! following! inhibitors:! ouabain! to! inhibit! the! Na+/K+FATPase,! α,βF
methylene! adenosine! 5’Fdiphophate! (APCP)! to! inhibit! the! conversion! of! AMP! to!
adenosine!by!CD73,!and!AKI!to! inhibit! the!conversion!of!ADP!into!ATP!and!AMP!by!
adenylate! kinase.! These! inhibitors! are! necessary! to! isolate! the! phosphohydrolysis! of!
ATP!by!CD39.!Control!cells!received!an!equal!volume!of!media.!The!reaction!mixture!
was! stopped! with! 8! M! formic! acid! and! spotted! onto! silica! gel! TLC! plates,! where!
nucleotides! were! separated.! The! enzymatic! activity! of! CD39! was! assessed! by!
densitometrically! measuring! the! relative! levels! of! [8F14C]ATP,! ! [8F14C]ADP,! and! [8F
14C]AMP.! ! Enzymatic! activity! increased!with! fluvastatin! treatment! relative! to! control!









for! 1! hr! at! RT! (Vectorlabs),! and! then! incubated! with! primary! antibodies! for! CD39!
(AbCam)! overnight! at! 4! °C! in! a! humid! chamber.! Slides! were! then! washed! and!
incubated! with! biotinylated! secondary! antiFmouse! antibodies! for! 30! minutes.! ABC!
reagent,! a! preformed! avidinFbiotin! peroxidase! complex,! (Vectorlabs)!was! then! added!
for!30!minutes!at!room!temperature.!A!tetramethylrhodamineFlabeled!tyramide!(PerkinF
Elmer)!was! added! for! 4!minutes! at! room! temperature,! and! then! slides!were!washed!
again.!In!dual!stained!slides,!the!procedure!was!repeated!for!a!second!set!of!antibodies!
for!CAV1!detection!(AbCam)!with!fluorescein!(PerkinFElmer).!In!the!final!set!of!washes,!
1! \g/mL! of!DAPI!was! added! as! a! counter! stain.! ! Slides!were!mounted!with! Prolong!
Gold! Antifade! Reagent! (Invitrogen),! and! slides! were! allowed! to! cure! in! the! dark! at!
room! temperature! for! 24! hours.! Slides! were! then! sealed! with! nail! polish! and!




HUVECs! were! fluorescently! labeled! with! antibodies! as! described! above! and!
visualized!using!a!100x!oil!objective!on!an!Olympus!IXF71!inverted!confocal!microscope.!
Each!image!shown!is!from!one!slice!of!a!zFseries.!After!DMSO!treatment,!cells!express!
basal! levels! of! CD39! and!CAV1! localized! to! the! plasma!membrane.! After! fluvastatin!
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a! rubber! policeman.! IceFcold! hypotonic! lysis! buffer! was! added! containing! 50! mM!
sucrose,! 10!mM!Hepes! pH! 7.4,! and! one! tablet! of! a! complete! protease! inhibitor! tablet!




cellular!debris.!Membranes!were!purified! from! the! supernatant!by! centrifuging! again!






minutes! at! 100! °C.! Proteins! were! then! loaded! onto! 10%! BisFTris! or! 4F12%! BisFTris!
polyacrylamide!gels.!!Gels!were!then!transferred!onto!PVDF!membranes,!blocked!for!1!
! 30!
hr! with! 5%!NFDM/0.05%! TBSFT,! and! then! incubated! with! primary! antibody! against!
CD39!(AbCam)!overnight!at!4!°C.!Membranes!were!then!washed!3x!in!TBSFT!and!then!
incubated! with! a! peroxidase! labeled! antiFmouse! secondary! antibody! (Sigma).!










CeCl3.! Cells! were! then! embedded! in! a! thin! layer! of! histopaque,! and! rinsed! in! TrisF









Human! CD39! cDNA! was! inserted! into! the! following! vector,! pcCALL2:!
CMV/Chicken!βFactin!promoter/enhancer,!followed!by!a!floxed!stop!signal!encoded!by!
three! consecutive! poly! A! sequences,! followed! by! multiple! cut! sites! for! the! gene!
insertion,! along! with! a! Neo! cassette! for! selection! (45).! Five! transgenic! founder! mice!
were!born,!and!were!bred!to!establish!the!transgenic!colony.!Transgenic!progeny!were!
crossed!with!tissueFspecific!Cre!mice!to!generate!mice!that!overexpress!human!CD39!in!
specific! tissues.! The! availability! of! speciesFspecific! antibodies! for! CD39! will! make! it!




! Lungs! from!mice!were! rinsed! briefly! in! PBS,! and!minced! thoroughly.!Minced!
tissue!was!then!transferred!to!into!2%!collagenase!A!in!PBS!for!40!minutes!at!37!°C!and!
then! pushed! through! an! 18! G! syringe.! The! resulting! homogenate! was! then! pushed!
through!a!50!\M!filter!and!washed!in!FACS!buffer!containing!5%!FBS!and!0.1%!NaN3!in!
PBS.! Red! cells! were! lysed! using! ACK! (ammoniumFchlorideFpotassium)! lysis! buffer!













CD39! mRNA! levels! increased! in! a! doseFdependent! manner! following! statin!
administration!(1!to!50!\M,!data!not!shown),!and!a!dose!of!10!\M!was!chosen!for!use!in!
all! subsequent! experiments.! This! dose!was! chosen! because! it!was! the! lowest! dose! at!
which! maximum! induction! of! CD39! was! observed.! ! A! time! point! of! 24! hours! was!





its! hydrophilic! nature! prevents! its! uptake! into! cells.! Silencing!CAV1! expression! (80%!
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decrease)! using! a! siRNA! against! CAV1! did! not! change! the! ability! of! fluvastatin! to!
increase!CD39!expression!(Figures!2.1B!and!2.1C).!
!
Figure! 2.1:! CD39! mRNA! increases! after! statin! treatment! but! CAV1! mRNA! is! not!
affected.!A)!HUVECs!were!treated!with!10!\M!fluvastatin!for!the!indicated!times!and!
CD39!mRNA!was!measured.!B)!HUVECs!were!treated!with!DMSO,!fluvastatin,!control!
















Figure! 2.2:! CD39! protein! increases! after! statin! treatment,! whereas! CAV1! protein!
decreases.!A)!HUVECs!were!treated!with!either!pravastatin!as!a!control!or!fluvastatin!
















expression! is! elevated! in! the! presence! of! statins,! and! the! expression! patterns! of! both!
CAV1!and!CD39!become!more!diffuse!and!less!localized!to!the!plasma!membrane!after!
statin!treatment.!!
Next,!activity!of!CD39!was!measured! in! the!presence!and!absence!of!statins,! in!






treated!with! either! fluvastatin! or!DMSO,! and! then! apyrase! activity!was!measured!by!
TLC.! Adenylate! kinase! inhibitor! (AKI)! and! APCP! were! added! in! order! to! prevent!
interconversion!of!adenine!nucleotides!and!inhibit!CD73!activity,!respectively.!!
!
The! conversion! of! labeled! ATP! to! AMP! was! greater! in! samples! containing!
fluvastatin! treated!HUVECs! (34%!versus! 16%).! !Ouabain! and! inhibitors! for! adenylate!







with!either!DMSO!or! fluvastatin!and! then!electron!micrographs!were! taken!along! the!




HUVECs!were! then! treated!with! fluvastatin! (10\M)!or!DMSO!and! imaged!via!
transmission! electron! microscopy! (TEM)! (Figure! 2.5).! The! images! show! that! the!
presence! of! fluvastatin! disrupts! the! formation! of! caveolae,! and! that! whatever!












of! statins! also! changed! the! posttranslational! state! of! CD39,!we! removed! all!NFlinked!
glycans!from!CD39.!Membrane!preparations!of!HUVECs!treated!with!either!DMSO!or!
fluvastatin! (10\M)!were! harvested! for! protein! analysis! by!Western! blot! (10%!BisFTris!
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gel).! Samples!were! incubated!with!PNGase!F! in! order! to!deglycosylate!CD39! (Figure!











construct! containing! a! chicken! βFactin! promter/CMV! enhancer! promoter! (blue)!
followed!by!a! floxed! stop! signal!was!obtained!and! the! sequence! for! full! length!CD39!
was!inserted.!In!the!presence!of!cre!recombinase,!the!stop!signal,!composed!of!a!polyA!
sequence,!is!excised,!and!transcription!is!enabled.!B)!Expressed!in!mice,!those!that!carry!






























promoter.! Lungs! from! transgenic! offspring! of! these!mice! expressing! the! recombined!
(active)!transgene!and!wild!type!mice!were!harvested!and!analyzed!by!flow!cytometry.!





after! statin! treatment! is! mediated! by! regulation! of! CD39! postFtranslational!




80! nm! in! diameter,! and! can! be! imaged! using! electron! microscopy! (41).! Functions!
attributed! to! caveolae! include! signal! transduction,! endocytosis,! suppression!of! eNOS,!
and! cholesterol! regulation.! Endothelial! caveolae! contain! caveolinF1! (CAV1)! proteins,!
which!are!associated!with!cholesterol,!and!which!are!required!to!form!their!ΩFshaped!
structures!(46).!Due!to!their!requirement!for!caveolinF1!and!cholesterol,!they!are!readily!
distinguished! from! lipid! rafts! by! caveolinF1! protein! expression,! and! demonstrably!
disrupted! by! several! methods! of! cholesterol! depletion! and! small! interfering! RNAs!
(siRNA)! against! CAV1.! Some! studies! indicate! that! the! structure! of! caveolae! may! be!
disrupted! in! the! presence! of! statins! (47,! 48),! as! inferred! by! measurements! of! CAV1!
protein,!and!observed!in!electron!micrographs!of!smooth!muscle!cells!(which!also!form!
caveolae,!but!with!CAV3!instead!of!CAV1).! !Electron!micrographs!of!CD39!enzymatic!
activity! showed!highly! concentrated,!punctate! areas!of! activity!on! the! surface!of! cells!
expressing! either! fullFlength!CD39! or!CFterminus! truncated!mutant!CD39! (6).!On! the!
other! hand,! the! NFterminus! truncated! mutantFCD39! expressing! cells! showed! no!
activity.!CD39! is!palmitoylated! at! the!NFterminus,! and! it! has! been!demonstrated! that!
this!specific!fattyFacid!modification!targets!CD39!to!caveolae.!Since!our!data!show!that!
CD39! remains! active! after! statin! treatment,! and!we! know! that! CD39! activity! is! kept!
suppressed! until! it! reaches! the! plasma! membrane,! it! follows! that! CD39! must! either!




localization! is! indeed! altered! by! statin! treatment,! then! it! leads! to! the! question! of!
whether! statins! specifically! affect! CD39! function.! Indeed,! the! activity! of! the!
vasculoprotective!endothelial!nitric!oxide!synthase!(eNOS),!another!protein!localized!to!
caveolae,!is!suppressed!by!interactions!with!caveolin!proteins!(42).!eNOS!activity!is!also!
increased! by! the! presence! of! statins,! which! deplete! caveolinF1! protein.! ! Our! initial!
results! suggest! that! such! a!mechanism!may! be! possible! in! the! case! of! CD39! as!well,!
since! the! presence! of! statins! appears! to! change! the! posttranslational! state! of! CD39!





! The! second! major! aim! of! this! project! was! to! determine! whether! statinFdriven!









CD39! is! an! important! vascular! enzyme,!which,! based! on! its! potential! as! a! target! for!
therapeutic! innovation! alone,! merits! further! study.! It! tips! the! balance! of! the! scale!
against! inflammation! and! against! thrombosis,! and! yet! there! are! many! questions!
pertaining! to! the! fundamental!aspects!of! this!enzyme’s! form,! function,!and!regulation!
that! have! not! been! answered! in! the! literature.! Added! to! this,! is! the! everFincreasing!





was!not!simply! to! further!our!knowledge!about! the!enzyme!CD39,!but! to!understand!
the! dynamic! adaptations! of! CD39! in! response! to! its! changing! environment.! ! In!
continuing! this! work! in! the! future,! many! questions! come! to! mind! that! should! be!
































































































































































































The$ first$ half$ of$ this$ research$ was$ originally$ published$ in$ The$ Journal$ of$ Biological$











ATP$ and$ ADP$ to$ AMP.$ However,$ mechanisms$ of$ CD39$ transcriptional$ and$ postQ
translational$ regulation$ are$ not$ well$ known.$ Here$ we$ show$ that$ CD39$ is$
transcriptionally$ upQregulated$ by$ cAMP$ and$ CD39$ expression$ and$ activity$ can$ be$
modulated$ by$ inhibition$ of$ phosphodiesterase$ 3$ (PDE3).$ RAW$ macrophages$ and$
human$ umbilical$ vein$ endothelial$ cells$ (HUVECs)$ were$ treated$ with$ the$ PDE3$
inhibitors$ cilostazol$ and$ milrinone,$ then$ analyzed$ using$ qRTQPCR,$
immunoprecipitation/Western$ blot,$ immunofluorescent$ staining,$ radioQthinQlayer$
chromatography,$ a$ malachite$ green$ assay,$ and$ ELISA.$ HUVECs$ expressed$ elevated$
CD39$protein$ (2Qfold$ [P<0.05]$ for$ cilostazol$ and$2.5Qfold$ [P<0.01]$ for$milrinone),$while$
macrophage$ CD39$ mRNA$ and$ protein$ were$ both$ elevated$ after$ PDE3$ inhibition.$
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HUVEC$ ATPase$ activity$ increased$ by$ 25%$ with$ cilostazol$ and$ milrinone$ treatment$
(P<0.05$and$P<0.01,$respectively),$as$did$ADPase$activity$(47%$and$61%,P<0.001).$There$
was$also$a$doseQdependent$elevation$of$soluble$CD39$after$treatment$with$8QBrQcAMP,$








The$ processes$ of$ thrombosis$ and$ inflammation$ contribute$ significantly$ to$ the$
severity$ and$ progression$ of$ numerous$ disease$ states,$ including$ stroke,$ deep$ vein$
thrombosis$(DVT),$and$atherosclerosis$(1,$2).$Extracellular$purinergic$signaling$through$
ATP$and$ADP$has$been$shown$to$be$a$potent$trigger$for$inflammatory$cell$recruitment$
and$ thrombosis.$ Modulating$ this$ pathway$ is$ the$ plasmalemmal$ ectonucleotidase,$
CD39/NTPDase1$ (ectonucleoside$ triphosphate$ diphosphohydrolase).$ $ CD39$ is$
expressed$by$a$number$of$cell$ types$including$endothelial$cells,$B$and$T$lymphocytes,$
and$monocytes$and$macrophages,$and$hydrolyzes$the$terminal$phosphate$of$ATP$and$
ADP$ in$an$enzymatic$ cascade$ that$generates$AMP$ (3Q5).$By$depleting$ the$potent$proQ













kinase$ A$ (PKA),$ which$ is$ located$ in$ the$ cytoplasm$ as$ an$ inactive$ heterotetramer$ of$
regulatory$and$catalytic$ subunits.$ cAMP$ liberates$ the$catalytic$ subunits,$which$allows$
their$translocation$into$the$nucleus.$The$catalytic$subunit$then$phosphorylates$a$serine$
residue$(Ser133)$of$CREB.$CREB$dimers$then$bind$to$CRE$sequences$(TGACGTCA)$in$the$
promoter$ of$ various$ genes.$ The$ phosphorylated$ serine$ of$ CREB$ can$ then$ act$ as$ a$
scaffold$ for$ the$ transcriptional$ coQactivator$ CREBQbinding$ protein$ and$ p300.$ This$





The$ role$ of$ cAMP$ in$ modulating$ vascular$ tone$ has$ been$ well$ established.$ In$
cardiac$myocytes,$ increased$cAMP$ leads$ to$ increased$contractility$and$ tachycardia.$ In$
vascular$ smooth$muscle,$ cAMP$ acts$ as$ a$ vasodilator,$ by$ activating$ cAMPQdependent$
protein$ kinase$ (PKA),$ which$ then$ phosphorylates$ myosin$ light$ chain$ kinase$ and$




importance$ of$ this$ CRE$ site$ to$ the$ regulation$ of$ functional$ CD39.$ In$ this$ work,$ we$
demonstrate$that$CD39$RNA$and$functional$protein$are$upregulated$potently$by$cAMP$









objective$ was$ to$ investigate$ additional$ facets$ underlying$ control$ of$ leukocyteQ
endothelial$interaction$in$thrombosis$and$inflammation.$$
Cilostazol$has$been$administered$as$a$safe$and$effective$drug$for$the$treatment$of$
claudication$ in$ peripheral$ arterial$ disease;$ it$ inhibits$ phosphodiesterase$ 3$ (PDE3),$ an$
enzyme$ that$depletes$ intracellular$ cAMP$by$hydrolyzing$ its$ 3’Qcyclic$phosphate$bond$
by$ competitively$ binding$ to$ the$ cAMPQspecific$ binding$ site$ of$ the$ PDE3$ (17,$ 18).$
Milrinone$ is$ used$ clinically$ in$ patients$ with$ heart$ failure$ to$ improve$ contractility.$
Milrinone$was$chosen$as$an$ independent$ tool$ to$confirm$the$effect$of$PDE3$ inhibition$
on$ the$ expression$ of$ CD39$ (19).$ The$ cell$ membraneQpermeable$ cAMP$ analogue,$ 8Q
BromoQcAMP$ was$ also$ used$ to$ increase$ intracellular$ cAMP.$ Here,$ we$ show$ that$
increased$ intracellular$ cAMP$ (through$ the$ specific$ inhibition$ of$ PDE3)$ leads$ to$ the$
upregulation$of$functional$CD39$protein$in$human$endothelial$cells$as$well$as$in$murine$
macrophages.$ Most$ significantly,$ we$ found$ that$ macrophages$ and$ endothelial$ cells$





NY,$ USA)$ unless$ specified.$ Human$ umbilical$ vein$ endothelial$ cells$ (HUVEC)$ were$
isolated$ from$ human$ umbilical$ cords$ based$ on$ previously$ described$ methods$ (21).$
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Fresh$ cords$were$washed.$ The$ umbilical$ vein$was$ attached$ to$ a$ 10$mL$ syringe,$ and$
flushed$ with$ isotonic$ saline$ buffer.$ The$ cord$ was$ incubated$ with$ 2%$ collagenase$ 3$
(Worthington$Biochemical$Corp.,$Lakewood,$NJ,$USA)$in$HBSS$buffered$with$HEPES$at$
37°C.$ Veins$ were$ then$ flushed$ with$ isotonic$ buffer,$ and$ the$ flow$ through$ was$
centrifuged$ at$ 4°C,$ 190$ x$ g,$ 7$minutes.$ Pellets$were$plated$ onto$ 35$mm$plates$ coated$
with$ 0.2%$gelatin.$Cells$were$ not$ used$beyond$passage$ 4.$ $ EBMQ2$media$ and$EGMQ2$





MO,$USA),$PDE3$ inhibitors$ (cilostazol$ (Sigma),$milrinone$ (Sigma)),$ or$DMSO$ (Fisher,$
Pittsburgh,$PA,$USA)$control$for$indicated$times$in$serumQ$and$supplementQfree$EBMQ2$
media$or$serumQfree$RPMI$1640$media.$$
Murine#Peritoneal#Macrophage# Isolation—Peritoneal#macrophages$were$ isolated$ as$
described$ previously$ (21).$ In$ brief,$ 10QweekQold$ male$ C57Bl6/J$ mice$ were$ injected$
intraperiQ$ toneally$with$3.0$ml$of$a$5%$thioglycollate$solution$ (BD$BioQ$sciences).$Four$
days$ later,$ macrophages$ were$ isolated$ by$ periQ$ toneal$ lavage$ and$ placed$ in$ iceQcold$
phosphateQbuffered$saline.$The$cells$were$plated$in$6Qwell$plates$at$a$concentration$of$1$






of$doses$of$ cilostazol$ (30Q100$mM)$or$DMSO$ (1$mL/mL)$ (22,$ 23).$After$ treatment,$ cells$
were$ washed$ twice$ in$ PBS,$ and$ then$ total$ RNA$ was$ isolated$ using$ RNAeasy$ kits$
(Qiagen,$ Valencia,$ CA,$ USA).$ cDNA$was$made$ using$ cDNA$ synthesis$ kits$ (Applied$
Biosystems,$Grand$ Island,$NY,$USA).$Real$ time$qPCR$was$ carried$out$using$ the$7000$
detection$ system$ (Applied$ Biosystems)$with$ 2x$ universal$mastermix$ and$ primers$ for$
human$ CD39$ and$ human$ β2$ microglobulin$ (Applied$ Biosystems).$ All$ data$ were$
normalized$to$β2$microglobulin.$$
Platelet?rich#Plasma#Isolation#and#Platelet#Aggregometry—#Mouse$blood$was$drawn$
from$ the$ inferior$ vena$ cava$ using$ a$ 20Qgauge$ needle$ containing$ 3.2%$ sodium$ citrate.$
One$ volume$ of$HT$ Buffer$ (137$mM$NaCl,$ 2.68$mM$KCl,$ 12$mM$NaHCO3,$ 0.36$mM$
NaH2PO4,$10$mM$HEPES,$0.2%$bovine$serum$albumin)$was$added$and$spun$at$50$x$g#
for$ 10$min$ at$ room$ temperature.$The$ citrated$blood$was$brought$back$ to$ the$original$
volume$with$HT$Buffer$and$spun$at$50$x$g#for$10$min$at$room$temperature.$PlateletQrich$
plasma$was$collected.$PlateletQrich$plasma$aggregometry$was$ then$performed$using$a$
ChronoQlog$ 560CA$with$ the$Aggro/Link$ 810.$ 1$ x$ 108$ platelets$ in$ 500$mL$ of$HT$buffer$





was$ isolated$ from$ RAW$ cell$ total$ genomic$ DNA$ using$ PCR.$ The$ primers$ (5’Q
CACTTACTCGGGCATGCTGTTGAACQ3’$ and$
5’CCCCCTGAAGGGTTTGGATCAAATCAGTTCTGGQ$3’)$were$designed$by$analysis$of$
the$ sequence$ of$ the$mouse$Cd39$ gene,$ 5’$ flank$ (GenBankTM$accession$ number$NM_$
009848).$ The$ 4555Qbp$ insert$ was$ subcloned$ into$ pCRQXLQ$ TOPO$ vector$ (Invitrogen)$
using$the$TOPO$XL$PCR$cloning$kit$(Invitrogen)$and$sequenced$to$confirm$identity.$
Construction# of# Mouse# Cd39# Promoter?Luciferase# Reporter# Plasmids# and# Site?directed#
Mutagenesis?# PCR# was$ used$ to$ amplify$ mouse$ CD39# promoterQluciferase$ reporter$
constructs$representing$5’Qdeleted$CD39#upstream$sequences,$and$these$PCR$products$
were$ subcloned$ into$ the$ pGL3Qbasic$ vector$ (Promega)$ using$ a$ T4$ ligase$ and$ Quick$
Ligasing$buffer$ (Promega).$ In$ these$PCRs,$ the$CD39#genomic$ clone$ (described$above)$
was$used$as$a$template.$The$5’Qdeletion$constructs$of$the$CD39#promoter$represent$the$
spans$Q250$to$+32$(pCD39/250)$and$Q52$to$+32$(pCD39/52).$The$Cd39#promoter$Q220$to$Q
189$ fragment$ (containing$ a$ CRE$ element)$ was$ cloned$ into$ pCD39/52$ to$ make$ the$
deletion$construct$pCD39/ΔCRE.$For$mutants,$oligonucleotides$used$for$priming$were$
synthesized$ based$ on$ 5’Qflanking$ region$ sequence$ of$ the$mouse$Cd39#gene.$ The$ siteQ$
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directed$mutants$of$the$pCD39/CREmut$constructs$were$generated$using$QuikChange$
siteQdirected$ mutagenesis$ kits$ (Stratagene).$ In$ these$ PCRs,$ the$ 5’Qdeletion$ construct,$
pCD39/250,$ was$ used$ as$ a$ template.$ Two$ mutated$ priming$ oligonucleotides$
representing$overlapping$sense$and$antisense$sequences$of$the$mutant$site$were$used$to$
amplify$the$entire$pGL3$plasmid$and$insert.$The$mutated$primers$are$shown$as$follows$
(target$ regions$ are$ indicated$ by$ underlines$ and$ alterations$ are$ indicated$ by$ boldface$
type):$ 5’QGAGTTTTGAACACATACTACCACAAGCCTAGAAAAAAGQ3’$ and$ 5’Q
CTTTTTTCTAGGCTTGTGGTAGTATGTGTTCAAAACTCQ3’.$ Forward$ and$ reverse$
DNA$ sequencing$ of$ inserts$ confirmed$ the$ sequences$ of$ all$ constructs$ employed$ for$
transfection$assays.$
Construction# of#Mouse#Creb1,#Atf2,# and#Dominant#Negative# Creb#Overexpression# Plasmids?#
The$cDNA$clones$of$mouse$Creb1$and$Atf2$were$ordered$from$ATCC.$Creb1$expression$










The$ siteQdirected$ mutants$ of$ the$ dominant$ negative$ Creb$ overexpression$ plasmid$
(pCREB/Ser133Mut)$ constructs$ were$ generated$ using$ QuikChange$ siteQdirected$
mutagenesis$kits$(Stratagene).$In$these$PCR$reactions,$pCREB1$was$used$as$a$template.$
The$ mutated$ priming$ oligonucleotides$ represented$ overlapping$ sense$ and$ antisense$
sequences$ of$ the$mutant$ site$ that$ amplified$ the$ entire$ pGL3$ plasmid$ and$ insert.$ The$
mutated$primers$are$shown$as$follows$(target$regions$are$indicated$by$underlines,$and$
alterations$ are$ indicated$ by$ boldface$ type):$ 5’Q
CCTTTCAAGGAGGCCTGCCTACAGGAAAATTTTGQ3’$ and$ 5’Q
CAAAATTTTCCTGTAGGCAGGCCTCCTTGAAAGGQ3’.$
Transient# Transfections—RAW# cells$ were$ coQtransfected$ using$ SuperFect$ transfection$
reagent$(Qiagen).$The$day$before$transfection,$RAW$cells$were$plated$on$12Qwell$plates$
(Costar)$with$ 1$ x$ 105$ cells/well$ and$grown$ in$RPMI$ 1640$ (Invitrogen)$ containing$ 10%$
fetal$ calf$ serum$ (Invitrogen).$ Cultures$ were$ incubated$ at$ 37$ °C$ in$ a$ humidified$
atmosphere$containing$5%$CO2$until$they$reached$50$–$80%$confluence.$The$cells$were$
coQtransfected$using$ 0.75$mg$of$Cd39#promoterQpGL3$ reporter$plasmid$ and$0.75$mg$of$
control$ plasmid,$ pCMV/βQgalactosidQ$ ase,$ which$ served$ as$ an$ internal$ control$ to$
normalize$transfection$efficiency,$as$well$as$7.5$mL$of$SuperFect$transfection$reagent$in$
75$ mL$ of$ serumQfree$ RPMI$ 1640$ medium.$ This$ was$ followed$ by$ incubation$ at$ room$
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temperature$ for$ 10$min,$ after$which$ the$ complexes$were$mixed$with$ 0.4$ml$ of$ RPMI$




Luciferase$ reporter$ assays$ were$ performed$ using$ a$ luciferase$ reporter$ assay$ system$
(Promega).$ Transfected$ cells$ were$ washed$ two$ times$ with$ cold$ phosphateQ$ buffered$
saline$ and$ then$ harvested,$ lysed,$ and$ assayed$ for$ luciferase$ activity$ by$ a$ VICTOR$
LIGHT$luminometer$(PerkinElmer$Life$Sciences).$βQGalactosidase$enzyme$activity$was$
measured$ using$ a$ βQgalactosidase$ enzyme$ assay$ system$ (Promega).$ Fifty$ mLof$ the$
sample$was$mixed$with$50$mL$of$2x$buffer$containing$200$mM$sodium$phosphate,$pH$
7.3,$ 2$ mM$ MgCl2,$ 100$ mM$ βQmercaptoethanol,$ and$ 1.33$ mg/ml$ oQnitrophenylQβQ
galactopyranoside$ in$ a$ 96Qwell$ plate.$ After$ incubating$ for$ 30$ min$ at$ 37$ °C,$ the$
absorbances$ of$ the$ samples$ were$ read$ at$ 420$ nm$ in$ a$ VersaMax$ tunable$ microplate$
reader$ (Molecular$Devices).$ For$ the$ overexpression$ experiments,$ RAW$ cells$were$ coQ







buffer$ (1%$ SDS,$ 10$ mM$ EDTA,$ 50$ mM$ Tris,$ pH$ 8.0,$ 1$ mM$ phenylmethylsulfonyl$
fluoride,$ 1$ mg/ml$ aprotinin,$ 1$ mg/ml$ leupeptin)$ 12$ times$ at$ 4$ °C$ using$ 15$ sonicating$
pulses$ at$ 30%$ output.$ The$ supernatant$ was$ divided$ into$ three$ tubes$ for$ subsequent$
immunoprecipitation.$ Samples$were$ precleared$ in$ immunoprecipitation$ buffer$ (0.01%$
SDS,$ 1.1%$ Triton,$ 1.2$ mM$ EDTA,$ 16.7$ mM$ Tris,$ pH$ 8.1,$ 167$ mM$ NaCl,$ 1$ mM$




ATF2$ (Thr71)$ antibody$ (Santa$Cruz),$ or$ rabbit$ IgG$were$ then$ added,$ and$ the$mixture$
was$placed$on$a$rotator$for$16$h$at$4$°C.$Immunoprecipitates$were$recovered$by$adding$
protein$ AQSepharose$ beads,$ which$ were$ washed$ for$ 5$ min$ with$ low$ salt$ immune$
complex$wash$buffer$(0.1%$SDS,$1%$Triton,$2$mM$EDTA,$20$mM$Tris,$pH$8.1,$and$150$
mM$NaCl)$and$then$for$5$min$with$high$salt$immune$complex$wash$buffer$(0.1%$SDS,$















as$ a$ negative$ control,$ cells$were$washed$ twice$with$ PBS$ (Invitrogen),$ scraped$with$ a$
rubber$policeman,$and$suspended$in$iceQcold$RIPA$buffer$supplemented$with$a$tablet$of$




Concentrations$were$ determined$ via$ a$ colorimetric$ protein$ assay$ (BioQRad,$Hercules,$
CA,$USA).#
Enzyme?linked# immunosorbent# assay# (ELISA)?# HUVEC$ were$ plated$ on$ 24Qwell$
plates$ (Corning,$ Tewksbury,$ MA,$ USA)$ coated$ with$ 0.2%$ gelatin$ and$ grown$ until$
confluent.$Cells$were$serumQstarved$for$6$hours$before$serumQfree$treatment$with$100,$
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250,$ 500,$ and$ 1000$ mM$ 8QBrQcAMP$ for$ 8$ hours.$ Media$ was$ transferred$ into$
microcentrifuge$tubes$(Eppendorf,$Hauppauge,$NJ,$USA),$and$samples$centrifuged$(500$
x$ g,$ 5$minutes,$ 4°C).$ 100$ mL$ of$ cellQfree$ supernatants$were$ then$ loaded$ onto$ 96Qwell$
plates$(NuncQNalgene,$Lafayette,$CO,$USA)$that$had$been$coated$overnight$at$4°C$with$
a$ rat$ antiQCD39$ antibodies$ (5ug/mL,$R&D$MAB4398),$ and$ then$ blocked$ for$ 1$ hour$ at$
room$temperature$with$4%$BSA$(Sigma)$in$PBS.$Standard$lanes$were$included$in$each$





conjugated$ to$ alkaline$ phosphatase$ (1:800,$ 1$ hour,$ room$ temperature,$ Sigma)$ was$
added.$Wells$ were$ then$washed$ three$ times,$ and$ 5$mg$ of$ pQNitrophenyl$ Phosphate,$
Disodium$ Salt$ (PNPP)$ in$ 5$ mL$ of$ diethanolamine$ buffer$ (Thermo$ Scientific,$ Pierce,$
Rockford,$IL,$USA).$Color$was$allowed$to$develop$for$up$to$30$minutes,$stopped$with$2$








lactate,$ tetrazolium$ salt$ (2Q(4Qiodophenyl)Q3Q(4Qnitrophenyl)Q5QphenylQ2HQtetrazolium)$
and$diaphorase,$and$a$red$formazan$product$was$allowed$to$develop.$Absorption$was$
then$measured$at$490$and$680$nm$using$a$SpectraMax$M5$microplate$reader.$$
Immunoprecipitation?# HUVEC$ were$ plated$ on$ 24Qwell$ plates$ (Corning)$ coated$
with$ 0.2%$ gelatin$ and$ grown$ until$ confluent.$ Cells$ were$ serumQstarved$ for$ 6$ hours$
before$serumQfree$treatment$with$250$mM$8QBrQcAMP$for$18$hours.$#
Cell$ supernatants$were$ collected$ on$ ice$ and$ incubated$with$ gentle$ rocking$ overnight$
with$ proteinQG$ agarose$ beads$ (Roche),$ and$ then$ incubated$ with$ antiQhuman$ CD39$
antibody$(Abcam,$Cambridge,$MA,$USA)$coated$beads$at$4°C.$Beads$were$washed$and$
purified$ CD39$ protein$ was$ eluted$ and$ quantified$ via$ standard$ Western$ blotting$
techniques.$$
cAMP#measurement:#Competitive#Enzyme#Immunoassay?#HUVEC$were$treated$with$
cilostazol$ (100$mM)$or$an$equivalent$volume$of$DMSO,$washed$ twice$ in$PBS$ to$wash$
away$traces$of$DMSO,$and$then$intracellular$cAMP$levels$were$measured$according$to$
manufacturer$ instructions$of$ the$competitive$enzyme$immunoassay$kit$ (Cayman,$Ann$
Arbor,$MI,$USA).$#
Immunofluorescence# ?# HUVEC$ were$ plated$ on$ 4Qwell$ plastic$ chamber$ slides$




(100,$ 200,$ 400$mM).$Cells$were$ then$ fixed$ for$ 15$minutes$with$ ice$ cold$methanol,$ and$
then$incubated$overnight$with$a$mouse$antiQCD39$antibody$(1:100)$at$4°C$followed$by$
biotinylated$horse$ antiQmouse$ IgG$ (1:100,$Vector$Laboratories,$Burlingame,$CA,$USA)$
for$1$hour$at$room$temperature.$An$avidinQbiotinQperoxidase$complex$was$formed$for$
30$ minutes$ at$ room$ temperature$ and$ then$ added$ to$ samples.$ $ Finally,$ a$
tetramethylrhodamine$ labeled$ tyramide$ was$ added$ (Perkin$ Elmer,$ Waltham,$ MA,$
USA).$ Nuclei$ were$ stained$ with$ DAPI.$ Slides$ were$ mounted$ with$ Prolong$ Gold$




14C]ATP$ (MP$ Biomedicals,$ Santa$ Ana,$ CA,$ USA)$ and$ 286$ mM$ AOPCP$ (Sigma)$ in$
Medium$199$ (Gibco),$ and$ incubated$ at$ 37°C$ for$ 30$minutes.$ $Reactions$were$ stopped$
using$ 8M$ formic$ acid$ and$ the$ reaction$mixture$was$ then$ spotted$ onto$ silica$ gel$ TLC$
plates$ (Fluka,$ Invitrogen).$ A$ ladder$ of$ [8Q14C]ATP,$ [8Q14C]ADP,$ and$ [8Q14C]AMP$ (MP$
Biomedicals)$was$used.$Nucleotides$were$separated$by$thin$layer$chromatography$with$
isobutyl$alcohol,$isoamyl$alcohol,$2Qethoxyethanol,$ammonia,$and$water$(9:6:18:9:15)$(5).$




Western# Blotting# Assay?# Total$ protein$ was$ quantified$ and$ added$ to$ 4x$ sample$
buffer$ (Invitrogen),$ boiled$ for$ 3$minutes$ at$ 100°C,$ separated$ by$ 10%$ SDSQPAGE,$ and$
electrophoretically$ transferred$ onto$ PVDF$membranes$ (Invitrogen).$Membranes$were$
probed$ with$ mouse$ monocolonal$ IgG1$ antiQCD39$ antibodies$ (Abcam)$ and$ HRPQ
conjugated$antiQmouse$antibodies$(Sigma),$and$then$autoradiographed$using$enhanced$
chemiluminescence$ (ECL$ detection$ system,$ Amersham$ Biosciences,$ Piscataway,$ NJ,$
USA).$#
Statistics?#Statistical$analysis$was$performed$using$analysis$of$variance$to$detect$
differences$ between$ groups.$ Groups$ were$ analyzed$ with$ a$ oneQway$ ANOVA,$ and$












protein$were$ isolated.$From$ these$ samples,$CD39$mRNA$ levels$were$measured$using$






ATP$ to$AMP$was$ increased$by$2.5Qfold$and$ that$platelet$ aggregation$was$ reduced$by$




Figure! 3.1:!Effect$ of$ cAMP$ on$CD39$ expression$ in$ primary$macrophage$ cultures.$ 10Q
weekQold$ male$ C57Bl6/J$ mice$ were$ injected$ intraperitoneally$ with$ 3.0$ ml$ of$ a$ 5%$
thioglycollate$ solution.$ Four$ days$ later,$ macrophages$ were$ isolated$ by$ peritoneal$
lavage,$ red$ blood$ cells$ were$ lysed,$ and$ remaining$ cells$ were$ plated.$ After$ 24$ h,$ the$
recovered$cells$were$pretreated$with$20$M$H89,$50$M$LY294002,$or$DSMO$(vehicle)$for$
20$ min.$ To$ this$ medium,$ 250$ M$ 8QBrQcAMP$ was$ added,$ after$ which$ the$ cells$ were$
allowed$to$ incubate$ for$2$h.$ $A)$Total$RNA$was$ then$ isolated$ from$the$plated$murine$
peritoneal$ macrophages,$ and$ qRTQPCR$ was$ used$ to$ assay$ levels$ of$ CD39$ mRNA.$
Isolated$ peritoneal$ macrophages$ were$ treated$ with$ 250$ 8QBrQcAMP$ for$ 16$ h$ before$







Figure! 3.2:$ cAMPQinduced$ CD39$ expression$ results$ from$ transcriptional$ activation$ at$
CREQlike$sites;$deletional$analysis$of$the$Cd39#promoter.!A)#Schematic$of$the$5’Qflanking$
region$of$the$mouse$Cd39#gene$with$its$CREQlike$binding$sites.$Transient$coQtransfection$
of$ RAW$ cells$ was$ performed$ using$ either$ pCD39/250,$ pCD39/52,$ or$ pCD39/D206;$
pCD39/CRE1mut;$ and$pCMV/βQgalactosidase.$B)$Cultures$were$ transfected$with$ each$
of$the$indicated$constructs$using$the$SuperFect$procedure,$and$then$cells$were$treated$
with$ 250$ mM$ 8QBrQcAMP.$ Luciferase$ activities$ were$ then$ determined.$ Relative$ firefly$
luciferase$activity$is$normalized$to$control$pCMV/βQgalactosidase$activity$(***,$p$<0.001$
compared$ with$ nonQtreated$ controls;$ ###,$ p$ <$ 0.001$ compared$ with$ pCD39/250Q
transfected$ and$ cAMPQtreated$ groups).$ C)#ChIP$ of$ CREB1$ or$ ATF2$ interaction$ with$
CD39$promoter$in$RAW$cells.$RAW$cells$were$treated$with$250$mM$8QBrQcAMP$for$30$
min.$ qRTQPCR$ products$ targeting$ Q239$ to$ Q172$ of$ the$ CD39# promoter$ are$ shown.$Ct#
values$of$ChIP$DNA$were$normalized$to$the$Ct#values$of$the$input$DNA.$***,$p<$0.001$
compared$with$nonQtreated$control.$(D$and$F)#Effect$of$CREB1$or$AFT2$overexpression$
on$ Cd39$ mRNA$ expression.$ RAW$ cells$ were$ transfected$ either$ with$ a$ pCREB1$
overexpression$ construct,$ a$ pATF2$ overexpression$ construct,$ a$ dominant$ negative$
“phosphorylationQresistant”$ CREB1$ overexpression$ construct$ (pCREB/Ser133Mut),$ or$
vector$alone.$After$48$h,$transfected$cells$were$treated$with$250$mM$8QBrQcAMP$for$5$h,$
total$RNA$was$ extracted$ for$ reverse$ transcription,$ and$quantitative$PCR$was$done$ to$
evaluate$Cd39$ (D),$Creb1$ (E),$ or$Atf2# (F)$mRNA$ levels.$ *,$ p<$ 0.05;$ **,$ p$ <0.01;$ ***,$ p<$




The$ CD39$ promoter$ sequence$was$ cloned$ 1000$ bp$ upstream$ of$ transcriptional$
start$ site$ (Figure!3.2A).$Transcriptional$ activity$ at$ the$promoter$ region$was$measured$
using$ a$ firefly$ luciferase$ reporter$ gene$ and$by$ truncating$ and$mutating$ the$promoter$
region$ in$order$ to$ identify$promoter$elements$ that$regulate$CD39.$PromoterQluciferase$
reporter$ constructs$ were$ transfected$ into$ RAW$ 264.7$ cells$ to$measure$ transcriptional$
response$in$the$presence$or$absence$of$8QBrQcAMP.$Luciferase$activity$was$increased$in$





bp$ away$ from$ the$ transcriptional$ start$ site.$ Analysis$ of$ the$ region$ showed$ that$ one$
transcription$factor$binding$site,$a$CRE,$was$located$in$the$Q210/Q203$region$of$the$CD39$
promoter.$ This$ site$was$designated$CRE1.$CRE1$ (pCD39/ΔCRE)$was$ fused$ to$ a$ short$






CD39$promoter.$After$ treatment$with$8QBrQcAMP,$ crossQlinked$RAW$cell$ lysates$were$
immunoprecipitated$ with$ antiQphosphorylated$ CREB1$ or$ antiQphosphorylated$ ATF2$
antibodies.$qRTQPCR$was$used$to$amplify$fragment$of$the$promoter$from$Q239$to$Q172.$
These$ChIP$data$show$that$binding$of$phosphorylated$CREB$and$phosphorylated$ATF2$







PCR$performed$ to$ evaluate$CD39$mRNA$ (Figure!3.2D),$CREB1$mRNA$ (Figure!3.2E),$
and$ ATF2$ mRNA$ (Figure! 3.2F).$ CD39$ levels$ were$ increased$ by$ cAMP$ treatment$ in$
emptyQvector$transfected$samples,$and$in$those$transfected$with$nonQmutated$pCREB1$












Figure! 3.3.$ A)$ CD39$ protein$ levels$ measured$ by$ ELISA$ after$ cAMP$ treatment:$
Supernatants$of$HUVEC$treated$with$either$PBS$(control)$or$8QBrQcAMP$were$measured$






The$ cellQpermeant$ cAMP$ analogue$ 8QBromoQcAMP$ was$ used$ to$ achieve$ a$
gradation$ in$ cAMP$ levels.$ ELISA$ data$ showed$ that$ CD39$ protein$ increased$with$ the$



















were$ treated$with$ 30$mM$ cilostazol$
for$18$hours$and$then$harvested$for$
measurement$ of$ total$ mRNA$ by$




















































prior$work$establishing$a$ link$between$cAMP$and$CD39.$Given$ the$significant$ role$of$
endothelial$ cells$ in$ the$maintenance$of$ vascular$homeostasis,$ human$ endothelial$ cells$
(HUVEC)$ were$ used$ to$ investigate$ whether$ endothelium$ stimulated$ by$ cAMP$ can$
result$ in$ the$ upregulation$ of$ CD39.$ To$ confirm$ that$ intracellular$ cAMP$ levels$ were$
indeed$elevated$after$ the$ indicated$ treatment$ times$using$PDE3$ inhibitors$ in$HUVEC,$
endogenous$cAMP$levels$were$measured$with$or$without$cilostazol$(Figure!3.6).$$$
































Figure! 3.6.$ Quantification$ of$ intracellular$
cAMP$ level:$ HUVEC$ treated$ with$ 100$ mM$
cilostazol$ show$ 2.97Qfold$ increase$ in$ cAMP$
levels$ (p<0.05,$ n=7).$Analysis$ of$ intracellular$







Results$ demonstrated$ that$ cAMP$ levels$ were$ significantly$ elevated$ with$ cilostazol$
treatments.$ Surprisingly,$ endothelial$ cells$ exhibited$ markedly$ different$ responses$ to$
cAMP$ elevation,$ compared$ with$ macrophages$ subjected$ to$ PDE3$ inhibition.$ While$
CD39$ protein$ levels$measured$ by$Western$ blot$ elevated$ after$ treatment$ (Figure! 3.7),$
there$was$no$change$in$mRNA$levels$for$CD39$(Figure!3.8),$indicating$that$the$increase$
























































































































18$hours$of$ treatment,$ cells$were$washed,$and$collected$ for$analysis$via$Western$blot.$






















































Since$CD39$mRNA$was$ not$ affected$ by$ treatment,$we$ considered$ the$ possibility$ that$
regulation$of$CD39$in$HUVEC$may$occur$via$posttranslational$modifications,$possibly$
involving$ changes$ in$ the$ intracellular$ trafficking$or$ release$ of$CD39.$Posttranslational$
control$ was$ supported$ by$ an$ immunoprecipitation$ assay$ probing$ for$ ubiquitinated$
CD39$(Figure!3.12).$$
Figure! 3.12.$ Effect$ of$ PDE3$
inhibition$ on$ ubiquitination$ of$
CD39:$HUVEC$were$ treated$ for$
18$ hours$ with$ 8QBrQcAMP$ or$
control$ PBS.$ Cells$ were$ then$
washed$ in$ PBS,$ harvested,$ and$
incubated$ with$ beads$ coated$
with$ antiQhuman$ CD39$
antibody.$ Beads$ were$ then$
washed$ and$ the$ protein$ eluted$
and$ analyzed$ via$Western$ blot.$
Membranes$ were$ first$ probed$
with$ antiQubiquitin$ antibody,$
then$ stripped$ and$ reprobed$
with$antiQhuman$CD39$antibody$
(n=3,$p<0.05).$Treatment$with$8Q




Here,$HUVEC$were$ treated$with$ either$ control$DMSO$or$ 8QBrQcAMP,$ followed$











































performed.$Nucleotides$were$ separated$ by$ thin$ layer$ chromatography$ (TLC)$ (Figure!
3.13).$Signal$density$indicates$the$relative$levels$of$nucleotides$present$in$samples$at$the$
time$of$measurement$and$thus$serves$as$a$measure$of$CD39$activity.$Peaks$1,$2$and$3$
correspond$ to$ ADP$ measured$ in$ HUVEC$ samples$ treated$ with$ DMSO$ (control),$
cilostazol,$or$milrinone,$respectively.$
Both$ cilostazol$ and$ milrinone$ increased$ CD39$ activity$ significantly$ compared$
with$ control$DMSOQtreated$HUVEC.$As$ a$ confirmatory$ test$ of$ relative$ differences$ in$











activity$ following$ PDE3$ using$ radioQthinQ
layer$ chromatography$ (TLC):$ Total$ cell$
lysates$ of$ HUVEC$ treated$ with$ either$
DMSO,$ cilostazol$ (50$ mM),$ or$ milrinone$
(200$mM$)$were$incubated$with$14CQlabeled$
ATP.$ Total$ ADP$ was$ measured$ and$
normalized$ to$ total$ protein$ and$ total$
radiation$ per$ lane$ (n=5,$ *$ =$ p<0.05,$ **$ =$
p<0.01$).$Peak$1$indicates$ADP$measured$in$
DMSO$ (control)$ treated$ samples,$ peak$ 2$
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Figure!3.14.$Measurement$of$inorganic$phosphate$generation$following$PDE3$inhibition$





































































































































Here,$ the$ presence$ of$ inorganic$ phosphates$ generated$ by$ the$ cleavage$ of$ ATP$
and$ADP$were$measured,$where$higher$concentrations$of$inorganic$phosphate$indicate$
greater$ apyrase$ activity.$ These$ measurements$ indicate$ that$ both$ ATPQ$ and$ ADPase$






conditions.$ Under$ normal$ conditions$ in$ the$ absence$ of$ stressors$ such$ as$
hypoxia/ischemia,$ high$ shear$ stress,$ and$ triggers$ for$ inflammation$
(cytokines/chemokines),$ CD39$ helps$ to$ maintain$ a$ homeostatic$ environment$ (27Q29),$
maintaining$ blood$ fluidity$ and$ inhibiting$ inflammation.$ In$ the$ presence$ of$ these$
injurious$conditions,$however,$one$of$ the$most$potent$signals$ for$platelet$aggregation,$
ADP,$ as$ well$ as$ proQinflammatory$ signals$ such$ as$ ATP,$ are$ released$ into$ the$
extracellular$ environment.$ When$ this$ occurs,$ the$ extracellular$ concentration$ of$ ADP$
and$ATP$ increases$markedly.$Low$ levels$ of$ATP$act$ as$ communication$between$ cells$
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that$no$injuries$are$present$(30),$and$most$receptors$that$bind$ATP$belonging$to$the$class$
of$ P2X$ receptors$ are$ maximally$ activated$ at$ these$ low$ concentrations.$ However,$ the$
P2X7$receptor$is$only$activated$at$the$high$levels$of$ATP$(>100$mM)(31,$32)$that$signal$
danger,$ and$ therefore$ is$ the$ main$ ATPQdriven$ signaling$ pathway$ of$ injury.$ The$
activation$ of$ this$ pathway$ leads$ to$ increased$ αmβ2$ integrins$ and$ increased$ leukocyte$
recruitment.$ In$ short,$ the$ presence$ of$ high$ local$ concentrations$ of$ ATP$ serves$ as$ an$
acute$ sign$ of$ danger$ and$ triggers$ greater$ inflammation.$ CD39$ acts$ to$ dissipate$ both$
ADP$ and$ATP,$ limiting$ thrombosis,$ coagulation$ and$ inflammation$ (29).$ Though$ this$
role$of$CD39$has$largely$been$determined,$many$questions$surrounding$the$regulation$
of$CD39$on$both$transcriptional$and$posttranslational$levels$remain$unanswered.$$
Pleiotropy# of# PDE# inhibition?# Endothelial$ cells$ have$ been$ described$ to$ express$
several$of$the$11$phosphodiesterase$family$members,$including$PDE2,$PDE4,$PDE3,$and$
PDE5$(33),$and$the$latter$three$of$these$have$been$targeted$for$a$diverse$range$of$clinical$
uses.$ For$ example,$ roflumilast$ and$ cilomilast$ are$ PDE4$ inhibitors$ developed$ for$ the$
treatment$ of$ chronic$ obstructive$ pulmonary$ disease,$ and$ other$ drugs$ targeting$ PDE4$
inhibition$have$been$researched$as$antiQdepressants$and$have$been$shown$to$ improve$
memory$ in$ a$ rodent$model$ (34,$ 35).$ PDE5$ inhibitors$ are$ best$ known$ for$ their$ role$ in$
facilitating$vascular$smooth$muscle$relaxation,$and$drugs$such$as$sildenafil$and$tadalafil$
have$ been$ developed$ for$ the$ treatment$ of$ erectile$ dysfunction$ and$ for$ treatment$ of$
pulmonary$ arterial$ hypertension$ (34,$ 36).$ PDE3$ inhibitors$ have$ also$ been$ a$ target$ of$
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interest,$particularly$useful$as$vasodilators$in$the$treatment$of$heart$failure,$and$two$of$
these$ were$ specifically$ used$ herein$ as$ a$ tool$ to$ modulate$ intracellular$ cAMP$ levels.$
PDE3$ is$ particularly$ interesting$ in$ relation$ to$ its$ potential$ effects$ on$ CD39,$ as$ it$ is$
important$for$regulating$platelet$aggregation$by$affecting$intracellular$cAMP$levels.$It$is$
to$this$class$that$cilostazol$and$milrinone$belong,$the$former$developed$as$a$vasodilator$
and$ platelet$ inhibitor$ and$ the$ latter$ as$ a$ regulator$ of$ cardiac$ contractility$ and$
vasodilator$in$the$treatment$of$heart$failure.$$#
Effects# of# PDE3# inhibition?# Cilostazol$ has$ been$ used$ in$ the$ treatment$ of$
intermittent$ claudication$ in$ the$ context$ of$ peripheral$ arterial$ disease$ (37).$ It$ is$ an$
antithrombotic$ that$acts$as$an$arterial$vasodilator$ (38)$and$has$been$shown$to$prevent$
platelet$ aggregation$ stimulated$by$ collagen,$ADP,$ epinephrine,$ thrombin,$ arachidonic$
acid,$and$shear$stress$(37,$39).$While$the$mechanism$of$action$of$cilostazol$has$yet$to$be$
fully$ elucidated,$ it$ is$ known$ that$ cilostazol$ acts$ as$ a$ specific$ inhibitor$ of$
phosphodiesterase$ III$ (PDE3).$ This$ inhibition$ of$ PDE3$ leads$ to$ an$ increase$ in$
intracellular$ cAMP$ levels,$which$ then$potentiates$other$ signaling$pathways$driven$by$
cAMP,$and$finally$results$in$vasodilation$and$suppression$of$platelet$aggregation$(40).$It$
is$different$ from$other$drugs$of$ its$class$such$as$milrinone,$ in$ that$cilostazol$may$also$
exert$ beneficial$ effects$ on$ the$ endothelium$ by$ reducing$ adenosine$ reuptake$ into$
endothelial$cells,$platelets,$erythrocytes,$and$myocytes,$thereby$increasing$extracellular$
adenosine$ signaling$ through$ A1$ and$ A2$ receptors$ (41,$ 42).$ Milrinone,$ in$ contrast$ to$
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cilostazol,$has$been$used$in$the$treatment$of$patients$with$heart$failure$(43).$Though$its$
halfQlife$ is$ considerably$ shorter$ than$ that$ of$ cilostazol,$ it$ has$ been$ shown$ to$ have$ a$
greater$stimulatory$effect$on$cAMP$in$ventricular$myocytes$compared$to$cilostazol,$and$






recently$ established$ that$ CD39$mRNA$ and$ protein$ can$ be$ increased$ in$murine$ RAW$
macrophages$ and$ murine$ peritoneal$ macrophages$ after$ exposing$ cells$ to$ 8QBrQcAMP$
(16).$ $ There$ are$ several$ cAMP$ response$ elements$ (44)$ in$ the$murine$ CD39$ promoter$
region,$ of$ which$ one$ is$ proximal$ to$ the$ transcriptional$ start$ site$ to$ regulate$ CD39$
directly.$The$human$CD39$promoter$region,$in$contrast,$has$a$handful$of$APQ1/creQlike$
sequences$ encoded$ distal$ to$ the$ start$ site,$ indicating$ that$ cAMPQdriven$ effects$ in$
endothelial$ cells$ may$ indeed$ be$ different$ from$ the$ direct$ transcriptional$ pathway$ in$
murine$macrophages.$This$is$particularly$evident$here,$where$inhibition$of$PDE3$led$to$
significant$ increases$ in$protein$expression$and$activity$of$endothelial$CD39,$but$ led$to$
no$differences$in$mRNA$levels$(Figures!3.7,!3.8,!3.9,!3.10,!3.11,!3.13,$and$3.14).$This$is$in$
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in$ rat$ skeletal$muscles.$ This$ activity$ seems$ to$ be$dependent$ in$part$ on$ an$ increase$ in$
intracellular$cAMP,$in$that$cAMP$levels$induced$by$a$β2Qagonist$led$to$the$suppression$




contains$ a$ RanBPM$ (or$ RanBP9)$ binding$ site$ on$ its$ NQterminus$ (47).$ RanBPM$ is$ a$
widely$ expressed$ protein,$ scaffolding$ protein$ that$ mediates$ interactions$ between$ the$
cytoplasmic$ domains$ of$ proteins$ and$ other$ signaling$ moieties,$ and$ its$ various$
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associated$activities$range$from$promoting$apoptosis$(48)$to$microtubule$reorganization$
(49).$ Relevant$ to$ this$ study,$ others$ have$ shown$ that$ protein$ binding$ to$ RanBPM$ can$
inhibit$ubiquitination$(50,$51).$These$data$suggest$that$CD39$association$with$RanBPM$
may$play$a$role$in$how$CD39$expression$is$regulated.$#
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injury' and' promote' inflammation' and' thrombosis.' Ectonucleoside' triphosphate'
diphosphohydrolase'1'(CD39),'an'enzyme'expressed'on'the'plasmalemma'of'leukocytes'





tissueIspecific'manner' with' specific' Cre' recombinase'mice.' Here,' we' generated'mice'
that' express' hCD39' globally,' by' crossing' these'mice'with' those' expressing' EIIA'Cre.'
Bone'marrow' analysis' showed' similar' endogenous' CD39'mRNA' between' transgenic'
(TG)'and'wild'type'(WT)'mice'while'expression'of'the'human'transgene'was'>3,600Ifold'
greater' than' the'mouse' gene' (p<0.0001,' n=3).' Cerebral' ischemia'was' induced' using' a'







contralateral' hemispheres' were' purified' for' flow' cytometric' analysis.' While'
contralateral' hemispheres' had' the' same' numbers' of' macrophages' and' neutrophils'
(CD45+/' F4/80+' and' CD45+/Ly6g+' respectively),' ischemic' hemispheres' from' TG'mice'
had'64%'fewer'infiltrating'macrophages'and'68%'fewer'neutrophils'(p<0.001,'n=8).''
This'is'the'first'report'of'transgenic'overexpression'of'CD39'in'mice'imparting'a'
protective' phenotype' following' stroke,' with' reduced' leukocyte' infiltration,' smaller'







in' those' areas' downstream' of' the' occlusion,' and' a' consequent' deficit' in' cognitive'
function.' Current' tools' used' to' mitigate' tissue' damage' caused' by' acute' thrombotic'
stroke'involve'the'use'of'aspirin,'or'reperfusion'by'fibrinolytic'treatment'such'as'tissue'
plasminogen' activator' (rtIPA),' but' this'must' be' administered'within' the' first' several'





specific' and' localized' treatments' capable' of' targeting' inflammation' and' thrombosis'
apart'from'hemostasis'are'necessary.''
One' molecular' target' that' is' being' considered' for' antithrombotic' and' antiI
inflammation' therapeutic' development' include' ectoIapyrases,' which' limit'
inflammation'and'thrombosis'by'enzymatically'degrading'extracellular'nucleotides'(6I
8).' Of' these' ectoIapyrases,' CD39' (ENTPD1)' is' the' dominant' form' expressed' on' the'
plasmalemma,' and' is' responsible' for' dissipating' the' proIinflammatory'ATP' and'proI
thrombotic' ADP' to' form' AMP' (8,' 9).' CD39Imediated' degradation' of' proIthrombotic'











Generation#of# transgenic#mice:'C57Bl/6'mice'were'used' to'generate'mice' that' selectively'
expressed'a'human'CD39'transgene.'A'backbone'construct'(pcallI2,'a'gift'from'the'Lobe'
laboratory)'was'modified' (13,' 14).'A'description'of' the' final' construct' is' as' follows:' a'
CAG' promoter' followed' by' two' LoxP' sequences' flanking' a' 3' repetitions' of' a' polyA'
sequence,' followed' by' the' starting' sequence' and' fullIlength' human' CD39' cDNA'
(Figure! 4.1).' The' sequence' was' purified' and' microinjected' into' fertilized' eggs.'
Transgenic' founders'were' identified' via' a' specific' PCR' screen' probing' human'CD39'
DNA.'Forward'primer:'5’'ACA'GGC'GTG'GTG'CAT'CAA'GTA'GAA'3’'and'Reverse'
primer:'5d'CCT'GGC'ACC'CTG'GAA'GTC'AAA'G'I3d.'
''Stable' colonies'were' established' and'maintained' before' breeding' to' EIIAICre'
mice.'EIIAICre'mice'have'Cre' expression'driven'by' the'EIIA'promoter,' and'are'often'
used'when'generating'mice'that'express'transgenes'globally,'including'in'the'germline'










Doppler' flow' probe' (Transonic' Systems' Inc.),' with' occlusion' was' defined' as' 80%'
reduction'in'blood'flow'sustained'for'10'minutes'(16).'The'flow'probe'then'remained'for'






isolated' using' RNAeasy' kits' (Qiagen).' cDNA' was' made' using' cDNA' synthesis' kits'
(Applied'Biosystems).'Real'time'qPCR'was'carried'out'using'the'7000'detection'system'
(Applied' Biosystems)' with' 2x' universal' mastermix' and' primers' for' human' CD39' or'
mouse'CD39'and'mouse'βIactin'(Applied'Biosystems).'All'data'were'normalized'to'βI
actin.#
WholeACell# Protein# IsolationA' Organs' were' harvested' from' transgenic' or' ageI
matched'wild'type'C57Bl/6'mice'and'immediately'homogenized'with'a'handheld'tissue'
homogenizer'in'iceIcold'RIPA'buffer'(25'mM'TrisIHCL,'150'mM'NaCl,'0.1%'SDS,'0.1%'
TritonIX100,' with' all' reagents' from' Sigma)' containing' protease' inhibitor' (Roche).'
Samples' were' incubated' on' ice' for' 20' minutes' before' centrifugation' on' a' desktop'
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centrifuge'for'10'minutes'at'13,000'x'g'at'4°C.'Resulting'supernatants'were'transferred'
to' new' tubes.' Concentrations'were' determined' via' a' colorimetric' protein' assay' (BioI
Rad).'The'samples'were'flash'frozen'in'aliquots'and'stored'at'I80°C.'
Western# Blotting# AssayA# Total' protein' was' quantified' and' added' to' 4x' sample'
buffer' (Invitrogen),' boiled' for' 3'minutes' at' 100°C,' separated' by' 10%' SDSIPAGE,' and'
electrophoreticallyItransferred' onto' PVDF'membranes' (Invitrogen).' Membranes' were'
probed' with' mouse' monocolonal' IgG1' antiICD39' antibodies' (Abcam)' and' HRPI
conjugated' antiImouse' antibodies' (Sigma),' and' then' autoradiographed' using' the'
enhanced' chemiluminescence' (ECL)' detection' system' (Amersham' Biosciences).' Blots'
were' then' washed' and' probed' with' mouse' monoclonal' βIactin' IgG1' conjugated' to'
peroxidase'(Sigma),'and'then'autoradiographed'using'enhanced'chemiluminescence.''
Multiplex#cytokine#assay#–#Ischemia'was' induced' in#ageImatched'male'wild' type'
and' transgenic' mice' for' 6' hours,' and' then' ipsilateral' (ischemic)' and' contralateral'




desktop' centrifuge' at' 4°C' for' 10' minutes.' Supernatants' were' collected' into' fresh'
microcentrifuge' tubes.'A'96Iwell' filter'plate'provided' in' the'mouse'cytokine'panel'kit'




for' normalization.' After' incubation' with' a' biotinylated' antibody' and' streptavidin,' a'
Luminex'100'was'used'to'read'the'plate.''
MRI' –' After' 48' hours' of' cerebral' ischemia,' prior' to' brain' harvest,' mice' were'
anaesthetized'with'a'mixture'of'2%'isoflurane'and'air,'and'placed'in'a'7.0'T'Varian'MR'
scanner' (183Imm' horizontal' bore).' Body' temperature' was' maintained' at' 37°C' with'
heated'air.'A'doubleItuned'volume'radioIfrequency'coil'was'used'to'scan'the'heads'of'





48'hours'after'MCAO(17).' 1:'normal' function;'2:' flexion'of' the' torso'and'contralateral'
forelimb'upon'lifting'of'the'animal'by'the'tail;'3:'circling'to'the'contralateral'side'with'




Brains'were'washed'with' sterile' PBS' on' ice,' and' then'minced'with' scissors.' Samples'
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were' then' transferred' into' gentleMACS' tubes' (Miltenyi)' and' cells' were' dissociated'
using'a'gentleMACS'dissociator'(Miltenyi).'Samples'were'then'passed'through'a'sterile'
18'g'syringe'ten'times'in'order'to'obtain'a'singleIcell'suspension.'Red'blood'cells'were'
lysed'by' incubating' samples'with'ACK' (AmmoniumIChlorideIPotassium)' lysis'buffer'
(Invitrogen)'for'6'minutes'at'room'temperature'in'the'dark.'Samples'were'then'washed'
and'then'mixed'with'a'30%'Percoll'solution,'and'centrifuged'at'1,400'x'g'at'4°C'for'10'
minutes' to' separate'myelin.'Cells'were' then'washed' twice' in'FACS'buffer' (0.5%'FBS,'
0.1%'sodium'azide' in'PBS),'and' then'100,000'cells'were'distributed' into'each' tube' for'
antibody' staining.' Each' experiment'was' performed'with' isotype' controls.' Cells'were'
blocked' for' 30'minutes' on' ice'with' FcIblock' (BD'Biosciences),' and' then' fluorescently'
labeled'antibodies'were'added'for'30'minutes'on'ice'in'the'dark.'Samples'were'washed'








antibodies,' and' then' the' signal' amplified' using' a' tyramide' signal' amplification' kit'
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(PerkinIElmer).' CD39,' P2X7' receptors,' and' TNFα' were' detected' using' primary'
monoclonal'mouse'(CD39'and'TNFα)'and'rabbit'(P2X7)'antibodies'(Abcam),'and'DAPI'
was'used'as'a'counter'stain.''






were' transferred' and' incubated' for' 3'days.'More'GMICSF'was' added' to'media,' after'
which'cells'were' incubated'for'4'more'days.'All'cells'were' then'split' into'appropriate'
experimental'wells'and'no'further'passaging'was'performed.'
Malachite#green#assay#to#measure#apyrase#activity#–#Bone'marrow'macrophages'were'
harvested' from' wild' type' and' CD39' globallyItransgenic' mice' and' plated' in' 24Iwell'
plates'(Corning).'Cells'were'washed'twice'in'PBS'before'the'addition'of'ATP'or'ADP.'
Supernatants'were' collected' and' transferred' to' a' flatIbottom' 96Iwell' plate.' Standards'
were'run'alongside'samples,'and'were'prepared'using'serial'dilutions'of'a'solution'of'
known' concentration' of' phosphate' into' the' same' background' buffer' as' the' samples'
being'measured.''Finally,'the'working'solution'for'the'malachite'green'assay'was'added'
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(Bioassay' Systems).' Plates' were' incubated' for' 25' minutes' before' reading' O.D.'
measurements'at'620'nm.''
StatisticsA#Statistical'analysis'was'performed'using'analysis'of'variance'to'detect'
differences' between' groups.' Groups' were' analyzed' with' a' oneIway' ANOVA,' and'




Identification# of# transgenic#mice# A#Conditional' transgenic' CD39'mice'were' generated' in'
order'to'investigate'the'protective'nature'of'CD39'in'the'event'of'cerebral'ischemia.'A'






of' genotype' and' phenotype:'
A)'A'map'of'the'plasmid'used'
to' generate' CD39' transgenic'
mice.' CD39' was' inserted'



















































































































































Figure! 4.1F:! Bone' marrow' was'
harvested' from' both' wild' type'
and'transgenic'mice,'macrophages'
were' grown,' and' phosphatase'
activity' was' measured.' ATP' or'
ADP'was' added' as' a' substrate' to'






(Figure!4.1B).'Mice'were' then'bred' to'EIIAIcre'mice'with' a'C57bl/6' background,' and'
transgenic' offspring' expressing' human' CD39' were' identified' using' a' second' PCR'
screen.'Brains'were'isolated'from'these'mice'in'order'to'measure'human'CD39'mRNA'
expression'in'tissue.''Transgenic'mice'expressed'human'CD39'mRNA,'and'endogenous'
levels'of'murine'CD39'were'no'different' from'wild' type'C57BL/6'mice' (Figure!4.1C).''
Western'blots'comparing'tissue'of'wild'type'mice'to'transgenic'mice'shows'that'CD39'is'
ubiquitously' overIexpressed' across' a' panel' of' different' organ' tissues.' (Figure! 4.1D,!
4.1E).'To'confirm'the'functional'significance'of'overexpressed'CD39,'a'malachite'green'
assay'was'performed'(Figure!4.1F)'on'bone'marrow'derived'macrophages'of'wild'type'
and' transgenic' mice.' This' assay' measures' generation' of' inorganic' phosphate' from'
precursor' substrates.' These' results' demonstrate' that' phosphohydrolysis' of' ATP' and'















































macrophages' (BMDM)' from' transgenic' mice' compared' to' wild' type'mice.' Complete'
blood'counts'were'also'taken'(Table!4.1)'from'wild'type'and'transgenic'mice'in'order'to'
determine'whether' any'downstream'differences' could'be' accounted' for' by'decreased'







White'blood'cell'(K/oL)' 2.293'±''1.54' 2.95'±'2.422' ns'
Neutrophils'(K/oL)' 0.15'±''0.118' 0.397'±'0.475' ns'
Lymphocytes'(K/oL)' 2.083'±''1.476' 2.498'±'1.942' ns'
Monocyte'(K/oL)' 0.22'±''0.385' 0.0417'±'0.031' ns'
Eosinophil'(K/oL)' 0.005'±''0.005' 0.01'±'0.009' ns'
Basophil'(K/oL)' 0.002'±''0.004' 0.003'±'0.005' ns'
Red'blood'cell'(M/oL)' 7.23'±''1.234' 7.492'±'1.192' ns'
Hemoglobin'(g/dL)' 9.933'±''1.988' 10.067'±'1.529' ns'
Hematocrit'(%)' 36.05'±''6.742' 36.517'±'5.871' ns'
Mean'corpuscular'volume'(fL)' 49.7'±''1.276' 48.717'±'0.708' ns'
Mean'corpuscular'hemoglobin'(pg)' 13.65'±''0.74' 13.467'±'0.446' ns'
Mean' corpuscular' hemoglobin'
concentration'(g/dL)' 27.467'±''1.122' 27.633'±'1.033' ns'
Red'cell'distribution'width'(%)' 15.45'±''0.599' 16.567'±'1.194' ns'
Platelets'(K/oL)' 246.667'±''115.59' 262.333'±'149.396' ns'
'








contralateral' hemispheres' using' flow' cytometry.' Cell' counts' for' total' leukocytes,'
macrophages' and' neutrophils,' in' the' nonIstroke' (contralateral)' hemisphere' did' not'
differ' between' WT' and' TG' mice.' Recruitment' of' macrophages' was' drastically'
suppressed' in' ischemic' hemispheres' of' transgenic' mice' (Figure! 4.2A).' Similarly,'
recruitment' of' neutrophils' was' also' suppressed' in' the' ischemic' hemispheres' of'















































































































Figure! 4.3:' Transgenic' mice' have' smaller' infarct' volumes.' MCA' of' wild' type' and'
transgenic'mice'were'occluded'for'48'hours,'and'then'mice'were'anesthetized'in'order'
to' image'brains'via'MRI.' Scans'of'wild' type' (A)' and' transgenic' (B)'mouse'brains' are'
shown'in'coronal'slices'moving'from'anterior'to'posterior'sections,'where'white'areas'







































































Triphenyl' tetrazolium' chloride' (TTC)' staining' was' also' performed' to' visualize'
corresponding' tissue' death' following' MCAO' (Figure! 4.4).' TTC' dissolved' in' PBS' is'
nearly' colorless' until' active' mitochondria' in' living' tissue' reduce' TTC' to' 1,3,5I
triphenylformazan,'which'is'red.''Brains'of'wild'type'mice'were'observed'to'have'much'
larger' areas' of' inactive' tissue' in' ischemic' hemispheres' relative' to' transgenic' mice,'
which'had'much'more'contained'inactive'regions.''
CD39#overexpression#leads#to#differential#cytokine#expression#following#cerebral#ischemia#'I'Six'
hours' after' inducing' cerebral' ischemia,' brains' were' harvested' and' contralateral' and'
ipsilateral'hemispheres'were'isolated'separately,'and'homogenized'in'order'to'analyze'
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cytokine' expression' via' a' multiplex' protein' panel' (Figure! 4.5).' Cytokine/chemokine'
expression' levels' in' contralateral' hemispheres' of'wild' type' and' transgenic'mice'were'
not' different' from' each' other.' However,' ischemic' hemispheres' of' wild' type' mice'
showed' elevated' levels' of' proIinflammatory' cytokines' and' chemokines.' Classically'
designated' antiIinflammatory' cytokines' showed' mixed' patterns' of' expression.' IlI4'
showed'no'significant'differences'between'any'of'the'hemispheres,'whereas'wild'type'
ipsilateral' hemispheres' showed' greater' IlI5' expression' compared' to' transgenic'














wild' type' and' transgenic' mice' were' occluded' for' before' freezing' in' OCT.' Coronal'
sections'of'transgenic'and'wild'type'mouse'brains'were'stained'for'A)'TNFIα'shown'in'
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limited' relative' to' the' wild' type' mouse.' The' contralateral' image' further' shows' that'
there' is' elevated'CD39'present' in' the' TG'mouse,' as' expected.'Figure! 4.6B' shows' the'
distribution' of' P2X7' receptors' after' stroke.' P2X7' receptor' is' widely' expressed' in'
macrophages'and'other' circulating' leukocytes' (18),' and'as' expected,' it' can'be' seen' in'
ischemic' hemispheres' of' both' mice,' whereas' nonIischemic' hemispheres' appear'
unaffected.' Again,' transgenic' mouse' brains' express' higher' levels' of' CD39' in'
contralateral' hemispheres' compared' to' wild' type' mice.' Figure! 4.6C' shows' coronal'
sections' of' tissueIspecific,' LysMICre/CD39' transgenic' mice.' These' mice' overexpress'





the' 2x' images' show' that' the' area' affected' by' MCAO' is' much' smaller' in' LysMICre'
transgenic' mouse' brains.' Notably,' there' appears' to' be' no' large' difference' in' CD39'
expression'between'contralateral'hemispheres.''
!
! The' contribution' of' CD39' expressed' on' myeloidIlineage' cells' was' tested' by'





























Figure! 4.7:' LysmICre' transgenic'
mice' have' smaller' infarct'
volumes.'MCA'of'wild' type'and'
LysMICre' transgenic' mice' were'
occluded' for' 48' hours,' and' then'
mice' were' anesthetized' in' order'
to' image' brains' via' MRI.' A)'
Scans'of'wild'type'and'transgenic'
mouse' brains' are' shown' in'
coronal' slices' moving' from'
anterior' to' posterior' sections,'
where' white' areas' indicate'
edematous' tissue.' B)' Cerebral'



















Though' some' effective' thrombolytic,' fibrinolytic,' and' antiIplatelet' treatments'
exist' which' promote' reperfusion' in' ischemic' tissue,' alternative' approaches' remain' a'
priority' target'because'current' treatments'are'also'associated'with'complications'such'
as'increased'risk'of'intracerebral'hemorrhage.'A'further'limitation'exists'in'the'narrow'





establishes'CD39' (ENTPDase1)'as'a' strong'mediator'of' thrombosis'and' inflammation.'
ATP' and'ADP,' potent' triggers' of' inflammation' and' thrombosis,' respectively,' can' be'
present'in'high'concentrations'in'localized'areas'of'tissue'damage.'The'apyrase'activity'




In' this' study,' we' have' developed' a' transgenic' mouse' that' globally' expresses'
elevated'levels'of'CD39,'and'has'the'potential'to'be'modified'further'to'express'greater'





promoter/enhancer'sequence.'This' is' the' first'description'of'such'a'mouse,'which'was'








Having' confirmed' the' expected' genotype' and' expected' protein' and' RNA'
expression'for'the'globallyItransgenic'mice,'we'have'shown'that'CD39'overexpression'
is' functional' at' baseline,' as' BMDMs' from' transgenic' mice' exhibited' more' apyrase'
activity' compared' to' wild' type.' Our' further' studies' have' shown' that' this' baseline'
difference' in' apyrase' activity' conferred' a' protective' effect' in' transgenic'mice' against'
inflammation'and'tissue'death'after'a'cerebral'ischemic'insult.'Most'intriguingly,'it'can'
be' seen' that'mice' that' only' overexpress' CD39' in' their'myeloid' lineage' cells' are' also'
protected'in'terms'of'infarct'size.'In'the'globally'CD39'transgenic'mice,'while'the'total'
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percentage' of' infiltrating' macrophages' and' neutrophils' was' not' affected,' total'
inflammation' was' significantly' decreased' in' the' first' 48' hours' after' stroke,' and' this'
difference'was'shown'to'be'confirmed'by'the'MRIs'showing'a'far'smaller'stroke'volume'
as'well' as'by'neurological' scoring'which' showed' that' transgenic'mice' suffered' fewer'
neurological' deficits' than' their' wild' type' counterparts.' These' results' were' visually'
confirmed' in' direct' TTC' staining' of' live' versus' dead' tissue,' where' wild' type' mice'
sustained'more'tissue'death'after'MCAO'relative'to'transgenic'mice.''
'
' Concordant' with' the' anatomic' cerebral' and' functional' protection' in' stroke'
conferred'by'transgenic'overexpression'of'CD39,'data'from'a'cytokine/chemokine'panel'
performed'on'tissue'from'mice'postIischemic'stroke'showed'a'less'inflammatory'postI
stroke' phenotype' in' CD39' TG' mice.' A' general' pattern' of' cytokine' expression'
manifested,' where' across' classically' proIinflammatory' cytokines,' levels' in' transgenic'
CD39' ischemic'hemispheres'were'systematically' lower' than' in' the'wildItype' ischemic'
hemispheres.'Contralateral'nonIischemic'hemispheres,'on'the'other'hand,'which'served'
as'controls,'did'not'appear'to'differ'between'the'two'genotypes.'More'importantly,'the'
overexpression' of' CD39' appears' to' enable' the' ischemic' hemisphere' to' generally'
maintain'the'same'cytokine'profile'as'observed'on'the'nonIischemic'contralateral'side.'




to'be'different' from'each'other' in'any'of' the'other'parameters' tested,' thus'supporting'
our' hypothesis' that' CD39' overexpression' is' responsible' for' the' protection' from'CNS'
inflammation'and' tissue'death.'The' role'of'TNFIα'across'models'of' cerebral' ischemia'
remains' in' discussion.'While' the' elevated' levels' of' TNFIα' in' acute' stroke' have' been'
shown' to' impair' survival,' inhibition' of' TNFIα' in' the' long' term' has' been' shown' to'




This' finding' that' elevated'CD39' levels' are' protective' in' the' setting' of' cerebral'
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trafficking! of!CD39! in! response! to! the!pharmaceutical! actions! of! cholesterolAsynthesis!
blockade.! In! this! effort,! we! observed! that! CD39,! a! protein! characterized! by!multiple!
glycosylation! sites,! which! are! integral! to! its! native! trafficking! and! correct! folding,! is!
postAtranslationally!modified! in! the! presence! of! statins.! Furthermore,! the! presence! of!
statins! downregulated! caveolinA1! protein,! which! is! necessary! for! the! formation! of!
caveolae,!and!disrupted!the!classical!caveolar!microdomain!in!which!CD39!is!known!to!
reside.! Additionally,! the! cellular! localization! of! CD39!was! altered! in! the! presence! of!
statins,!with!expression!patterns!becoming!more!diffuse!rather!than!punctate.!The!total!
expression! of! functional!CD39!was! also! elevated.! This! suggests! an! important! role! for!
cholesterol!biosynthesis!in!the!topographic!localization!of!CD39.!
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Taken! together,! these! data! suggest! that! intracellular! CD39! trafficking,! in! the!
presence! of! statins,! is! no! longer! directed! through! caveolae.! The! global! in# vivo!
downstream! effect! of! disrupting! the! canonical! trafficking! pathway! on! endogenous!
CD39! function! is! unknown.! Statins! have! been! shown! to! be! effective! as! primary!
preventative!drugs!for!cardiovascular!disease!(1,!2).!Because!they!are!highly!effective!in!
lowering!plasma!cholesterol,!they!are!in!wide!use.!The!role!of!CD39!as!an!enzyme!that!
maintains! homeostasis! of! the! vascular!milieu,! inhibits! platelet! aggregation! and! limits!
inflammation! is! supported,! and! work! from! this! lab! suggests! that! CD39! is!
atheroprotective!independent!of!statins!(Kanthi!et!al.,!manuscript!in!review).!!In!future!
work!towards!the!development!of!CD39!as!a!potential!therapeutic,!it!will!be!important!
to! know!how!CD39! expression! and! function! can!be! altered,! not! solely! in! response! to!
statins,! but! in! response! to! a! dynamic! in# vivo! environment.!With! this! goal! in!mind,! a!






















Earlier! experiments!described! in!Chapter! II! (Figures! 2.1A2.6)! show! that! statins! elevate!
CD39!mRNA,! protein,! expression! pattern,! and! activity.! This! experiment!will! address!
the!question!of!whether!it!is!the!cholesterolAlowering!function!of!statins!or!a!secondary!
action! of! statins! that! affects! CD39! expression.! HUVECs! will! be! treated! with! statin,!
mevalonate,!or!both.!!Mevalonate!is!formed!by!the!action!of!HMGACoA!reductase!in!the!
cholesterol!synthesis!pathway.!!All!statins!inhibit!this!step.!The!addition!of!mevalonate!











depleted!of! cholesterol,!and!controls!will! include!mevalonate,!as!well!as! cholestenone!
treatments.! Cholestenone! is! an! oxidation! product! of! cholesterol! (3).! Although! it! is!
similar! in! structure! and! can! be! delivered! to! cholesterolAdepleted! membranes,! the!
addition! of! cholestenone! does! not! restore! cholesterolAspecific! processes.! ! Its! use! here!
will! determine! whether! cholesterol! reconstitution! by! itself! can! affect! CD39! activity.!
Caveolar!morphology,!occupancy,!and!CD39!presence!and!activity!will!all!be!measured.!
With! respect! to! CD39! protein! measurements,! the! possibility! of! increased! CD39!
shedding!with!altered!cholesterol!levels!will!be!considered.!CD39!in!the!culture!media!
will! be!measured!by!ELISA! (5).! ! It! is! expected! that! the! caveolar! localization! of!CD39!
depends!on!cholesterol,!and!that!the!restoration!of!the!mevalonate!pathway!following!
statin! treatment!with!mevalonate!will! restore! caveolae! to! the! plasma!membrane! and!
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that! CD39! will! localize! to! caveolar! structures.! The! function! of! CD39,! however,! may!









with!methylAβAcyclodextrin,! a! reagent!used! to!disrupt! caveolae.!CD39! activity!will! be!
measured! in! the! presence! or! absence! of! statin! treatment! to! determine! whether! the!
presence!vs!absence!of!caveolae!affects!CD39!activity.!!
!
To#determine#whether# statin0induced# increases# in#CD39#expression# results# in# increased#CD39#
enzymatic#activity##
HUVECs! will! be! transfected! with! either! a! control! or! Cav1! siRNA,! and! then!
treated! with! either! a! statin! or! DMSO.! ThinAlayer! chromatography! will! be! used! to!
measure!CD39!activity.!A!second!set!of!HUVECs!will!also!be!tested!for!their!ability!to!
reduce! ADPAdependent! platelet! aggregation.! Purified! membranes! will! be! incubated!
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with! platelets,! and! platelet! aggregation!will! be!measured.! Higher! CD39! activity! will!
result! in! less! aggregation! of! platelets.! I! expect! that! statin! treatment! will! result! in!




In! order! to! quantitatively! assess! changes! in! the! relationship! between! caveolae!
and!CD39!after!statin!treatment,!caveolae!will!be!isolated!from!HUVECs!that!have!been!
treated!with!either!DMSO!or!statin,!and!CD39!protein!levels!will!be!measured.!Caveolae!
will! be! purified! according! an! established!method! that! isolates! caveolae! based! on! the!
buoyant! density! of! caveolae! (5),! in! order! to! avoid! detergentAbased! purification! of!
caveolae.!A!detergentAbased!protocol!may!inadvertently!solubilize!some!proteins!from!
caveolae,!and!fail! to!yield!a!full!complement!of!caveolar!proteins.!Briefly,!cells!will!be!
harvested! by! scraping,! homogenized! in! a! buffer! containing! 0.25! M! sucrose,! 1! mM!
EDTA,! and! 20! mM! Tricine,! pH! 7.8,! and! then! centrifuged.! The! resulting! postnuclear!
supernatant!fraction!will!then!be!overlaid!onto!a!30%!Percoll!solution!and!centrifuged!at!
84,000!x!g!for!30!minutes.!A!visible!band!containing!the!plasma!membrane!fraction!will!
be! collected,! and! sonicated.! The! sonicate! will! be! placed! into! 23%! OptiPrep! (SigmaA
Aldrich).!A!20!to!10%!linear!gradient!of!OptiPrep!poured!on!top!of!the!sample,!and!the!







To#measure#whether# there# are# differences# in#CD39# posttranslational#modifications# after# statin#
treatment#





by! statin! treatment.!As! an! alternative! approach! to! test! glycosylation! sites! affected! by!
statin!treatment,!lentiviruses!expressing!glycosylation!site!mutants!of!HAAtagged!CD39!
will! be! designed! and! used! to! transduce! COS7! cells.! These! cells! will! be! treated! with!
either!DMSO!or!fluvastatin,!and!assessed!for!CD39!activity!by!TLC!as!described!above.!
A! second! set! of! similarly! treated! cells! will! be! surfaceAbiotinylated.! CD39! will! be!
precipitated! using! streptavidinAagarose! beads.! Precipitated! proteins!will! be! separated!
via!Western!Blot,!and!probed!for!HA,!to!assess!relative!levels!of!CD39!expression!on!the!
surface! and! enable! calculation! of! relative! ATPase! activity! of! different! CD39s.! From!
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been! identified.! Lentiviruses! expressing! HAAtagged! CD39! or! phosphorylation! site!
mutants!will!be!used!to!transduce!COS7!cells.!Cells!will!be!treated!with!either!DMSO!or!
fluvastatin!over!a!time!course.!HAACD39!will!be!visualized!using!immunofluorescence!





or! artificially! affecting! levels! of! CD39! in! the! caveolae! may! prove! to! be! difficult.!
Alternative!protocols!for!caveolar!isolation!are!available!for!testing!(8,!9).!For!example,!
while! many! methods! call! for! a! final! step! of! antibodyAcoated! bead! separation,! some!
methods! call! for! either! an! addition! of! detergent,! sonication,! or! both.! More! involved!
methods!also!include!the!initial!step!of!silica!coating!of!the!plasma!menbrane!in!order!to!
promote!more!efficient! separation!of!plasma!membrane! regions! from!caveolae,!which!
will! not! be! coated! due! to! their! invaginated! structure.! These! various!methods!will! be!
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To! test! the! hypothesis,! there! will! be! one! condition! with! caveolae! present! in!
endothelial! cells,! and! one! condition! without! caveolae! in! endothelial! cells.! Therefore!
normal! WT! mice! will! be! compared! to! Cav1! mutant! mice,! which,! due! to! a! targeted!
mutation!over!exons!1!and!2!of!CAV1,#produce!no!detectable!protein!products,!and!have!
been! shown! to! lack! endothelial! caveolae.!Mice! overexpressing! CD39!will! be! used! to!
show!effects!of!CD39!overexpression!that!are!separate!from!statin!treatment.!!
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! Fluvastatin! will! be! administered! by! gavage! at! a! dose! of! 80! mg/kg/d! for! two!





!! To! determine!whether! any! changes! in!CD39! activity,!CD39! localization,!CAV1!
expression! and! caveola! formation! are! cholesterolAdependent,! mice! will! be! injected!





All! three! types! of!mice!will! also! be! treated!with! fluvastatin! (80!mg/kg/d! for! 1!
month)!and!analyzed!as!described!above!in!order!to!ascertain!whether!statins!can!elicit!
responses! in! accord! with! results! from! Aim! 1.! After! 1! month! of! fluvastatin!
administration,!aortas!will!be!harvested.!CAV1,!and!CD39!protein!expression!patterns!







In! order! to! confirm! the! in# vitro! results! that! show! impaired! caveolar! structure!
formation! in! HUVECs,! caveolinA1! levels! will! be! evaluated! in! mouse! aortas! after!
fluvastatin!or!agarose!treatment.!These!aortas!will!be!harvested!for!caveolinA1!mRNA,!
protein,! IHC,! and! electron!microscopy.! It! is! expected! that!WT! and!CD39OE!mice!will!
have!diminished!caveolae/caveolinA1!protein!after!fluvastatin!treatment,!whereas!Cav1!
mice!will!not!exhibit!any!changes!in!terms!of!caveolae/caveolinA1!expression.!CaveolinA1!
mRNA! levels! are! not! expected! to! change.! In! the! event! that! statin! treatment! does! not!
result!in!any!significant!decrease!in!caveola!formation,!then!the!possibility!that!caveolae!
may! be! affected! by! statins! through! other! parallel! pathways! will! be! considered.! For!
example,! in!nonAendothelial!cells,! some!have!reported!an! increase! in!Cav1!after!statin!
treatment! (10).! Investigating! the! reason! for! these! differential! responses! to! statin!
treatment!based!on!cell!type!may!lead!to!either!an!explanation!for!a!lack!of!statin!effect!
on! caveolae! in# vivo,! or! information! on! other! mechanisms! of! caveolar! regulation.!





To#determine#whether# changes# in#CD39#activity#are#due# to# changes# in#geographic# localization#
and#post0translational#modifications#of#CD39#
! Since! glycosylation! has! been! shown! to! determine! CD39! activity,! this!NAlinked!
modification!will!be!explored!first.!Mice!will!be!treated!with!fluvastatin!or!agarose,!and!
then!their!aortas!harvested!for!IHC!and!an!electron!microscopyAbased!measurement!of!
CD39! activity! and! Cav1! expression.! Mass! spectrometry! will! also! be! performed! on!
protein! samples! purified! from! aortas! of! similarly! treated! mice,! in! order! to! analyze!
glycosylation!and!phosphorylation!of!CD39.!
It! is!expected! that! in!mice!of!all!groups!will! show!an! increase! in!CD39!activity!
and!glycosylation!levels!after!treatment!with!fluvastatin,!regardless!of!whether!caveolae!
are!present.!It!is!also!expected!that!CD39OE!and!WT!mice!will!show!an!increase!in!CD39!















The! second! project!was! designed! to! understand!CD39! protein! upregulation! in!
cells,! and! in# silico# analysis! suggested! that! cAMP! may! be! an! important! regulator! of!
CD39.! One! CREAlike! sequence! was! found! proximal! to! the! start! site! of! CD39!
transcription! in! the!CD39!promoter,! and! treatment! of!RAW!macrophages! and!mouse!
peritoneal! macrophages! with! 8ABromoAcAMP! elevated! CD39! RNA,! protein,! and!
activity.!Truncations!of!the!putative!promoter!binding!site!resulted!in!a!loss!of!cAMPA
induced! reporter! gene! expression.! Further! analysis! of! the! binding! site! through! ChIP!




made!the! following!three!conclusions.!The!first!was! that!CD39!modulation! is!possible!
using!a! currently! approved!and! safely!utilized! class!of!drugs,!PDE3! inhibitors.!While!
evidence! for! the! protective! effects! of! CD39! against! thrombosis! and! excessive!
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The! second! conclusion!of! this!project!was! that!CD39! expression! in! response! to!
cAMP!modulation! is!controlled!differently! in!macrophages!and!endothelial!cells.!This!
work!furthers!understanding!in!dealing!with!CD39!in!a!systemic!setting,!and!provides!
further! insight! into!different!pathways!of!CD39! regulation.!Whereas! in!macrophages,!
the! pathway! of! CD39! upregulation! by! cAMP! is! transcriptional,! endothelial! CD39!
upregulation! by! cAMP! appears! to! be! driven! at! the! level! of! postAtranslational!






! To!date,! there! is! very! little! published! information! regarding! protein! turnover! of!







mutating! these! sites! decreases! ubiquitination! of! CD39! and! increases! CD39! protein!
stability.! If! so,! there! may! be! implications! for! future! CD39Aderived! therapies.! For!
example,! prolonged! protein! stability! as! a! result! of! mutated! ubiquitination! sites! is! a!
known! concept,! particularly! in! the! context! of! tumor! cells! (13).! In! a! therapeutic!
approach,! techniques! that! deliberately! inhibit! ubiquitination! have! been! suggested! for!





The! third! and! final! project! was! designed! to! observe! the! effects! of! globally!
elevated!CD39!in!a!murine!model,!and!specifically!in!the!setting!of!cerebral!ischemia.!!A!
novel!transgenic!mouse!was!created!using!a!CreALox!transgenic!construct!to!be!able!to!





When! cerebral! ischemia! was! induced! in! each! mouse! model,! both! strains! of!
transgenic!mice!exhibited!significantly!smaller! stroke!volumes!compared! to!wild! type!
mice! as! measured! by! MRI.! Both! were! also! more! protected! from! adverse! stroke!
outcomes! compared! to!wild! type!mice!according! to!neurological!deficit! scoring.!Mice!
expressing! human! CD39! globally! also! had! less! infiltration! of! leukocytes! into! the!
ischemic! hemisphere.! In! a! panel! of! cytokines! measured! in! brains! of! wild! type! and!






Future!work! on! this! project!may! include! an! increased! range! of! time! points! of!
ischemia,!in!order!to!investigate!the!effect!of!CD39!upregulation!on!both!early!and!late!
stroke.!It!will!also!be!important!to!determine!whether!CD39!upregulation!has!any!effect!
on!blood! flow!and!clot!dissipation! in! the!context!of!cerebral! ischemia,!or!whether! the!
observed! decrease! in! injury! in! transgenic! mice! can! be! attributed! solely! to! decreased!
inflammation! overall.! Furthermore,! the! strain! of! mice! expressing! human! CD39!
specifically!in!myeloid!lineage!cells!will!be!tested!further.!
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The! field! of! CD39! research! is! still! growing.! While! significant! findings! about!
CD39!have!emerged! since! its!discovery,! there! is! still!very! little!known!about! its!most!
basic!qualities.!For!example,!until!2012,!there!was!no!crystal!structure!available!of!CD39,!
and! now! further! research! can! be! performed! on!manipulation! of!CD39! to! increase! its!
efficiency.!!
CD39! has! been! established! as! a! potentially! promising! therapeutic! target! in!
ameliorating! the! harmful! effects! of! thrombosis! and! to! an! increasing! extent,!
inflammation.!The!work!described!herein!has!contributed!meaningfully!to!this!body!of!
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